1A1M | B:1-99; A:182-272 | MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE TPYDINQML FROM GAG PROTEIN OF HIV2 |
1A1N | B:1-99; A:182-272 | MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTY FROM THE NEF PROTEIN (75-82) OF HIV1 |
1A1O | B:1-99; A:182-272 | MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) FROM THE MALARIA PARASITE P. FALCIPARUM |
1A22 | B:332-432; B:233-331 | HUMAN GROWTH HORMONE BOUND TO SINGLE RECEPTOR |
1A6A | A:82-180; B:94-191 | THE STRUCTURE OF AN INTERMEDIATE IN CLASS II MHC MATURATION: CLIP BOUND TO HLA-DR3 |
1A6Z | B:1-99; D:1-99; A:183-273; C:183-273 | HFE (HUMAN) HEMOCHROMATOSIS PROTEIN |
1A8J | H:2-111; L:2-111; H:112-212; L:112-212 | IMMUNOGLOBULIN LAMBDA LIGHT CHAIN DIMER (MCG) COMPLEX WITH ASPARTAME |
1A9B | B:1-100; E:1-100; A:182-272; D:182-272 | DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS |
1A9E | B:1-100; A:182-272 | DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS |
1AD0 | A:108-210; B:114-211; D:114-211; B:1-113; D:1-113; C:108-210; A:1-107; C:1-107 | FAB FRAGMENT OF ENGINEERED HUMAN MONOCLONAL ANTIBODY A5B7 |
1AD9 | A:108-208; B:114-212; H:114-212; B:1-113; H:1-113; L:107-210; L:1-106; A:1-107 | IGG-FAB FRAGMENT OF ENGINEERED HUMAN MONOCLONAL ANTIBODY CTM01 |
1ADQ | A:338-443; L:2-107; L:108-211; A:238-337; H:1-113; H:114-223B | CRYSTAL STRUCTURE OF A HUMAN IGM RHEUMATOID FACTOR FAB IN COMPLEX WITH ITS AUTOANTIGEN IGG FC |
1AGB | B:1-99; A:182-272 | ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MUTATION) |
1AGC | B:1-99; A:182-272 | ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MUTATION) |
1AGD | B:1-99; A:182-272 | ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX PEPTIDE) |
1AGE | B:1-99; A:182-272 | ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MUTATION) |
1AGF | B:1-99; A:182-272 | ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKRYKL-5R MUTATION) |
1AH1 | A:1A-131 | CTLA-4, NMR, 20 STRUCTURES |
1AKJ | B:2-99; A:182-270; D:1-114; E:1-114 | COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 AND THE T CELL CORECEPTOR CD8 |
1AO7 | B:0-99; A:182-270; E:3-117; E:118-243; D:1-121 | COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201 |
1AQD | A:82-181; D:82-179; G:82-179; J:82-179; K:93-191; B:93-190; E:93-190; H:93-190 | HLA-DR1 (DRA, DRB1 0101) HUMAN CLASS II HISTOCOMPATIBILITY PROTEIN (EXTRACELLULAR DOMAIN) COMPLEXED WITH ENDOGENOUS PEPTIDE |
1AQK | H:124-223; L:2-111; L:112-212; H:2-123 | THREE-DIMENSIONAL STRUCTURE OF A HUMAN FAB WITH HIGH AFFINITY FOR TETANUS TOXOID |
1AR2 | A:1-109 | DISULFIDE-FREE IMMUNOGLOBULIN FRAGMENT |
1AXI | B:132-232; B:32-131 | STRUCTURAL PLASTICITY AT THE HGH:HGHBP INTERFACE |
1B0G | B:0-99; A:182-270; D:182-270; E:0-99 | CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX |
1B0R | B:400-499; A:182-270 | CRYSTAL STRUCTURE OF HLA-A*0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUTED BY A METHYL GROUP |
1B0W | A:1-108; B:1-108; C:1-108 | STRUCTURAL COMPARISON OF AMYLOIDOGENIC LIGHT CHAIN DIMER IN TWO CRYSTAL FORMS WITH NONAMYLOIDOGENIC COUNTERPARTS |
1B3J | A:181-274 | STRUCTURE OF THE MHC CLASS I HOMOLOG MIC-A, A GAMMADELTA T CELL LIGAND |
1B4J | L:108-211; L:1-107; H:2-117; H:118-217 | COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF A HUMANIZED AND A CHIMERIC FAB OF AN ANTI-GAMMA-INTERFERON ANTIBODY |
1B6D | A:108-211; B:108-211; A:1-107; B:1-107 | BENCE JONES PROTEIN DEL: AN ENTIRE IMMUNOGLOBULIN KAPPA LIGHT-CHAIN DIMER |
1B6U | A:103-203; A:5-102 | CRYSTAL STRUCTURE OF THE HUMAN KILLER CELL INHIBITORY RECEPTOR (KIR2DL3) SPECIFIC FOR HLA-CW3 RELATED ALLELES |
1BBJ | A:109-211; B:115-212; H:115-212; L:109-211; B:2-114; H:2-114; A:1-108; L:1-108 | CRYSTAL STRUCTURE OF A CHIMERIC FAB' FRAGMENT OF AN ANTIBODY BINDING TUMOUR CELLS |
1BD2 | B:1-99; A:182-270; E:3-118; D:117-201; E:119-244; D:1-116 | COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201 |
1BEY | L:109-211; H:122-219; H:1-121; L:1-108 | ANTIBODY TO CAMPATH-1H HUMANIZED FAB |
1BJ8 | A:1-109 | THIRD N-TERMINAL DOMAIN OF GP130, NMR, MINIMIZED AVERAGE STRUCTURE |
1BJM | A:2-111; B:2-111; A:112-212; B:112-212 | LOC NAKS, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN NAKSO4 |
1BOY | A:3-105; A:106-213 | EXTRACELLULAR REGION OF HUMAN TISSUE FACTOR |
1BP3 | B:202-301; B:302-404 | THE XRAY STRUCTURE OF A GROWTH HORMONE-PROLACTIN RECEPTOR COMPLEX |
1BPV | A:0-103 | TITIN MODULE A71 FROM HUMAN CARDIAC MUSCLE, NMR, 50 STRUCTURES |
1BQS | A:91-209; A:1-90 | THE CRYSTAL STRUCTURE OF MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) |
1BQU | A:105-214; B:105-213; A:5-104; B:5-104 | CYTOKYNE-BINDING REGION OF GP130 |
1BRE | A:1-107; B:1-107; C:1-107; D:1-107; E:1-107; F:1-107 | IMMUNOGLOBULIN LIGHT CHAIN PROTEIN |
1BVK | A:1-108; B:1-116; E:1-116; D:1-108 | HUMANIZED ANTI-LYSOZYME FV COMPLEXED WITH LYSOZYME |
1BWW | A:1-109; B:1-109 | BENCE-JONES IMMUNOGLOBULIN REI VARIABLE PORTION, T39K MUTANT |
1BX2 | A:82-181; D:82-181; B:92-193; E:92-191 | CRYSTAL STRUCTURE OF HLA-DR2 (DRA*0101,DRB1*1501) COMPLEXED WITH A PEPTIDE FROM HUMAN MYELIN BASIC PROTEIN |
1C8P | A:1-102 | NMR STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE COMMON BETA-CHAIN IN THE GM-CSF, IL-3 AND IL-5 RECEPTORS |
1CCZ | A:1-93; A:94-171 | CRYSTAL STRUCTURE OF THE CD2-BINDING DOMAIN OF CD58 (LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 3) AT 1.8-A RESOLUTION |
1CD0 | B:1-107; A:1-108 | STRUCTURE OF HUMAN LAMDA-6 LIGHT CHAIN DIMER JTO |
1CD8 | A:1-114 | CRYSTAL STRUCTURE OF A SOLUBLE FORM OF THE HUMAN T CELL CO-RECEPTOR CD8 AT 2.6 ANGSTROMS RESOLUTION |
1CD9 | D:2-108; B:1-108; B:109-213; D:109-212 | 2:2 COMPLEX OF G-CSF WITH ITS RECEPTOR |
1CDB | A:1-105 | STRUCTURE OF THE GLYCOSYLATED ADHESION DOMAIN OF HUMAN T LYMPHOCYTE GLYCOPROTEIN CD2 |
1CDH | A:1-98; A:99-173 | STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES |
1CDI | A:1-98; A:99-173 | STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES |
1CDJ | A:1-98; A:99-173 | STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 |
1CDU | A:1-98; A:99-173 | STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH PHE 43 REPLACED BY VAL |
1CDY | A:1-98; A:99-173 | STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH GLY 47 REPLACED BY SER |
1CG9 | B:1-100; A:182-272 | COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6 |
1CI5 | A:1-95 | GLYCAN-FREE MUTANT ADHESION DOMAIN OF HUMAN CD58 (LFA-3) |
1CN4 | A:119-220; B:119-220; A:22-118; B:22-118 | ERYTHROPOIETIN COMPLEXED WITH EXTRACELLULAR DOMAINS OF ERYTHROPOIETIN RECEPTOR |
1CVS | C:149-249; D:149-249; C:250-359; D:250-358 | CRYSTAL STRUCTURE OF A DIMERIC FGF2-FGFR1 COMPLEX |
1CZ8 | L:109-211; H:124-223; Y:124-223; H:1-123; Y:1-123; X:109-211; L:1-108; X:1-108 | VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH AN AFFINITY MATURED ANTIBODY |
1D5M | A:82-181; B:92-190 | X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH PEPTIDE AND SEB |
1D5X | A:82-181; B:92-190 | X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH DIPEPTIDE MIMETIC AND SEB |
1D5Z | A:82-180; B:92-190 | X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH PEPTIDOMIMETIC AND SEB |
1D6E | A:82-180; B:92-190 | CRYSTAL STRUCTURE OF HLA-DR4 COMPLEX WITH PEPTIDOMIMETIC AND SEB |
1DAN | U:91-210; T:6-80 | COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR |
1DCL | A:1-111; B:1-111; A:112-212; B:112-212 | MCG, A LAMBDA V TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN), CRYSTALLIZED FROM AMMONIUM SULFATE |
1DE4 | B:1-99; E:1-99; H:1-99; A:183-273; D:183-273; G:183-273 | HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRIN RECEPTOR |
1DEE | C:1109-1211; B:501-621; D:1501-1621; F:2501-2621; B:622-723; D:1622-1723; F:2622-2723; A:108-211; E:2108-2211; A:1-107; E:2001-2107; C:1001-1108 | CRYSTAL STRUCTURE AT 2.7A RESOLUTION OF A COMPLEX BETWEEN A STAPHYLOCOCCUS AUREUS DOMAIN AND A FAB FRAGMENT OF A HUMAN IGM ANTIBODY |
1DFB | L:108-209; H:127-226; H:1-126; L:1-106 | STRUCTURE OF A HUMAN MONOCLONAL ANTIBODY FAB FRAGMENT AGAINST GP41 OF HUMAN IMMUNODEFICIENCY VIRUS TYPE I |
1DJS | A:147-250; A:251-362 | LIGAND-BINDING PORTION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 IN COMPLEX WITH FGF1 |
1DL7 | L:1-109; H:1-112 | THE STRUCTURAL BASIS OF REPERTOIRE SHIFT IN AN IMMUNE RESPONSE TO PHOSPHOCHOLINE |
1DLH | A:82-181; D:82-181; B:93-190; E:93-190 | CRYSTAL STRUCTURE OF THE HUMAN CLASS II MHC PROTEIN HLA-DR1 COMPLEXED WITH AN INFLUENZA VIRUS PEPTIDE |
1DN0 | A:110-212; A:1-109; C:1-109; B:1-120; D:1-120; D:121-222; B:121-222; C:110-212 | STRUCTURE OF THE FAB FRAGMENT FROM A HUMAN IGM COLD AGGLUTININ |
1DN2 | A:338-443; B:338-443; A:238-337; B:238-337 | FC FRAGMENT OF HUMAN IGG1 IN COMPLEX WITH AN ENGINEERED 13 RESIDUE PEPTIDE DCAWHLGELVWCT-NH2 |
1DQL | L:1-106; H:2-123 | CRYSTAL STRUCTURE OF AN UNLIGANDED (NATIVE) FV FROM A HUMAN IGM ANTI-PEPTIDE ANTIBODY |
1DR9 | A:1-105; A:106-200 | CRYSTAL STRUCTURE OF A SOLUBLE FORM OF B7-1 (CD80) |
1DUY | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF HLA-A*0201/OCTAMERIC TAX PEPTIDE COMPLEX |
1DUZ | B:0-99; E:0-99; A:182-270; D:182-270 | HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) IN COMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN |
1E0O | B:149-250; D:149-250; B:251-359; D:251-359 | CRYSTAL STRUCTURE OF A TERNARY FGF1-FGFR2-HEPARIN COMPLEX |
1E27 | B:1-99; A:182-272 | NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM1(LPPVVAKEI) |
1E28 | B:1-99; A:182-272 | NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM2(TAFTIPSI) |
1E4J | A:87-172; A:2-86 | CRYSTAL STRUCTURE OF THE SOLUBLE HUMAN FC-GAMMA RECEPTOR III |
1E4K | A:338-443; B:338-443; A:238-337; B:238-337; C:87-172; C:2-86 | CRYSTAL STRUCTURE OF SOLUBLE HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR III COMPLEX |
1EAJ | B:20-139; A:16-139 | DIMERIC STRUCTURE OF THE COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR D1 DOMAIN AT 1.35 ANGSTROM RESOLUTION |
1EBA | A:119-220; B:119-218; A:22-118; B:22-118 | COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN INACTIVE PEPTIDE [EMP33] CONTAINS 3,5-DIBROMOTYROSINE IN POSITION 4 (DENOTED DBY) |
1EBP | A:119-220; B:119-220; A:22-118; B:22-118 | COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN AGONIST PEPTIDE [EMP1] |
1EEQ | A:1-107; B:301-407 | M4L/Y(27D)D/T94H MUTANT OF LEN |
1EER | B:119-220; C:119-220; C:22-118; B:24-118 | CRYSTAL STRUCTURE OF HUMAN ERYTHROPOIETIN COMPLEXED TO ITS RECEPTOR AT 1.9 ANGSTROMS |
1EEU | A:1-106; B:301-407 | M4L/Y(27D)D/Q89D/T94H MUTANT OF LEN |
1EEY | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE DETERMINATION OF HLA A2 COMPLEXED TO PEPTIDE GP2 WITH THE SUBSTITUTION (I2L/V5L/L9V) |
1EEZ | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE DETERMINATION OF HLA-A2.1 COMPLEXED TO GP2 PEPTIDE VARIANT(I2L/V5L) |
1EFQ | A:1-107 | Q38D MUTANT OF LEN |
1EFX | B:0-99; A:182-272; D:103-200; E:103-200; D:5-102; E:5-102 | STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3 |
1EGJ | L:109-211; L:1-108; H:114-223; H:1-113; A:338-438 | DOMAIN 4 OF THE BETA COMMON CHAIN IN COMPLEX WITH AN ANTIBODY |
1EK3 | A:1-108; B:301-408 | KAPPA-4 IMMUNOGLOBULIN VL, REC |
1ERN | B:119-220; A:119-218; A:19-118; B:19-118 | NATIVE STRUCTURE OF THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] |
1EV2 | E:150-250; F:150-250; G:151-250; H:151-250; H:251-357; G:251-357; F:251-357; E:251-357 | CRYSTAL STRUCTURE OF FGF2 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 (FGFR2) |
1EVT | C:149-249; D:149-249; D:250-357; C:250-357 | CRYSTAL STRUCTURE OF FGF1 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1) |
1EVU | A:517-630; B:517-630; A:631-725; B:631-725; A:8-192; B:8-192 | HUMAN FACTOR XIII WITH CALCIUM BOUND IN THE ION SITE |
1EX0 | A:517-630; B:517-630; A:631-725; B:631-725; A:8-192; B:8-192 | HUMAN FACTOR XIII, MUTANT W279F ZYMOGEN |
1EXU | B:1-99; A:176-266 | CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR |
1F13 | A:516-630; B:516-630; A:631-727; B:631-727; B:8-192; A:8-192 | RECOMBINANT HUMAN CELLULAR COAGULATION FACTOR XIII |
1F2Q | A:4-84; A:85-174 | CRYSTAL STRUCTURE OF THE HUMAN HIGH-AFFINITY IGE RECEPTOR |
1F42 | A:103-210; A:1-84; A:214-304 | THE P40 DOMAIN OF HUMAN INTERLEUKIN-12 |
1F45 | A:103-210; A:1-84; A:214-302 | HUMAN INTERLEUKIN-12 |
1F5W | B:19-139; A:16-139 | DIMERIC STRUCTURE OF THE COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR D1 DOMAIN |
1F6A | B:436-543; D:436-543; A:4-84; B:336-435; D:336-435; A:85-173 | STRUCTURE OF THE HUMAN IGE-FC BOUND TO ITS HIGH AFFINITY RECEPTOR FC(EPSILON)RI(ALPHA) |
1F6L | L:1-106 | VARIABLE LIGHT CHAIN DIMER OF ANTI-FERRITIN ANTIBODY |
1FAK | T:6-105; T:106-206 | HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT |
1FC1 | A:338-443; B:338-443; A:238-337; B:238-337 | CRYSTALLOGRAPHIC REFINEMENT AND ATOMIC MODELS OF A HUMAN FC FRAGMENT AND ITS COMPLEX WITH FRAGMENT B OF PROTEIN A FROM STAPHYLOCOCCUS AUREUS AT 2.9-AND 2.8-ANGSTROMS RESOLUTION |
1FCC | A:338-443; B:338-443; A:238-337; B:238-337 | CRYSTAL STRUCTURE OF THE C2 FRAGMENT OF STREPTOCOCCAL PROTEIN G IN COMPLEX WITH THE FC DOMAIN OF HUMAN IGG |
1FCG | A:90-174; A:4-89 | ECTODOMAIN OF HUMAN FC GAMMA RECEPTOR, FCGRIIA |
1FE8 | L:108-211; H:116-214; I:116-214; J:116-214; H:1-115; I:1-115; J:1-115; M:108-211; N:109-211; L:1-107; M:1-107; N:1-108 | CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR A3 DOMAIN IN COMPLEX WITH A FAB FRAGMENT OF IGG RU5 THAT INHIBITS COLLAGEN BINDING |
1FG9 | D:109-220; E:109-219; C:109-224; C:12-108; D:12-108; E:13-108 | 3:1 COMPLEX OF INTERFERON-GAMMA RECEPTOR WITH INTERFERON-GAMMA DIMER |
1FH5 | L:110-212; H:121-213; H:4-120; L:2-109 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THE MONOCLONAL ANTIBODY MAK33 |
1FIE | A:516-630; B:516-630; A:631-725; B:631-724; A:9-192; B:10-192 | RECOMBINANT HUMAN COAGULATION FACTOR XIII |
1FLT | X:132-226; Y:132-225 | VEGF IN COMPLEX WITH DOMAIN 2 OF THE FLT-1 RECEPTOR |
1FNA | A:6-96 | CRYSTAL STRUCTURE OF THE TENTH TYPE III CELL ADHESION MODULE OF HUMAN FIBRONECTIN |
1FNF | A:1416-1508; A:1142-1235; A:1327-1415; A:1239-1325 | FRAGMENT OF HUMAN FIBRONECTIN ENCOMPASSING TYPE-III REPEATS 7 THROUGH 10 |
1FNH | A:3-92; A:93-182; A:183-271 | CRYSTAL STRUCTURE OF HEPARIN AND INTEGRIN BINDING SEGMENT OF HUMAN FIBRONECTIN |
1FNL | A:90-175; A:5-89 | CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF A HUMAN FCGRIII |
1FP5 | A:436-543; A:336-435 | CRYSTAL STRUCTURE ANALYSIS OF THE HUMAN IGE-FC CEPSILON3-CEPSILON4 FRAGMENT. |
1FQ9 | C:149-249; D:149-249; C:250-359; D:250-358 | CRYSTAL STRUCTURE OF A TERNARY FGF2-FGFR1-HEPARIN COMPLEX |
1FV1 | A:82-181; D:82-181; B:93-190; E:93-190 | STRUCTURAL BASIS FOR THE BINDING OF AN IMMUNODOMINANT PEPTIDE FROM MYELIN BASIC PROTEIN IN DIFFERENT REGISTERS BY TWO HLA-DR2 ALLELES |
1FVC | C:1-108; B:1-120; D:1-120; A:1-109 | X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING |
1FVD | A:109-211; B:121-220; D:121-220; B:1-120; D:1-120; C:109-211; A:1-108; C:1-108 | X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING |
1FVE | A:109-211; B:121-220; D:121-220; B:1-120; D:1-120; C:109-211; A:1-108; C:1-108 | X-RAY STRUCTURES OF THE ANTIGEN-BINDING DOMAINS FROM THREE VARIANTS OF HUMANIZED ANTI-P185-HER2 ANTIBODY 4D5 AND COMPARISON WITH MOLECULAR MODELING |
1FYH | B:109-222; E:109-221; B:12-108; E:12-108 | 1:1 COMPLEX BETWEEN AN INTERFERON GAMMA SINGLE-CHAIN VARIANT AND ITS RECEPTOR |
1FYT | E:3-118; D:117-202; A:82-181; E:119-246; B:93-190; D:1-116 | CRYSTAL STRUCTURE OF A COMPLEX OF A HUMAN ALPHA/BETA-T CELL RECEPTOR, INFLUENZA HA ANTIGEN PEPTIDE, AND MHC CLASS II MOLECULE, HLA-DR1 |
1G0X | A:97-198; A:2-96 | CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF LIR-1 (ILT2) |
1G0Y | R:98-203; R:204-315; R:6-97 | IL-1 RECEPTOR TYPE 1 COMPLEXED WITH ANTAGONIST PEPTIDE AF10847 |
1G1C | A:2-99; B:2-99 | I1 DOMAIN FROM TITIN |
1G84 | A:1-105 | THE SOLUTION STRUCTURE OF THE C EPSILON2 DOMAIN FROM IGE |
1GGT | A:516-630; B:516-630; A:631-729; B:631-725; A:8-192; B:8-192 | THREE-DIMENSIONAL STRUCTURE OF A TRANSGLUTAMINASE: HUMAN BLOOD COAGULATION FACTOR XIII |
1GGU | A:517-630; B:517-630; A:631-724; B:631-724; A:8-192; B:8-192 | HUMAN FACTOR XIII WITH CALCIUM BOUND IN THE ION SITE |
1GGY | A:517-630; B:517-630; A:631-724; B:631-724; A:8-192; B:8-192 | HUMAN FACTOR XIII WITH YTTERBIUM BOUND IN THE ION SITE |
1GH7 | A:109-215; B:109-215; A:320-416; B:320-416; A:1-95; B:1-95; A:218-308; B:218-308 | CRYSTAL STRUCTURE OF THE COMPLETE EXTRACELLULAR DOMAIN OF THE BETA-COMMON RECEPTOR OF IL-3, IL-5, AND GM-CSF |
1GSM | A:91-206; A:1-90 | A REASSESSMENT OF THE MADCAM-1 STRUCTURE AND ITS ROLE IN INTEGRIN RECOGNITION. |
1GXE | A:1-130 | CENTRAL DOMAIN OF CARDIAC MYOSIN BINDING PROTEIN C |
1GYA | A:1-105 | N-GLYCAN AND POLYPEPTIDE NMR SOLUTION STRUCTURES OF THE ADHESION DOMAIN OF HUMAN CD2 |
1GZP | B:0-99; A:183-278 | CD1B IN COMPLEX WITH GM2 GANGLIOSIDE |
1GZQ | B:0-99; A:183-278 | CD1B IN COMPLEX WITH PHOPHATIDYLINOSITOL |
1H0D | A:108-203; A:1-107; B:114-212; B:1-113 | CRYSTAL STRUCTURE OF HUMAN ANGIOGENIN IN COMPLEX WITH FAB FRAGMENT OF ITS MONOCLONAL ANTIBODY MAB 26-2F |
1H15 | A:82-181; D:82-181; B:93-190; E:93-190 | X-RAY CRYSTAL STRUCTURE OF HLA-DRA1*0101/DRB5*0101 COMPLEXED WITH A PEPTIDE FROM EPSTEIN BARR VIRUS DNA POLYMERASE |
1H3T | A:338-443; B:338-433; A:238-337; B:238-337 | CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (MN2F)2 |
1H3U | A:338-443; B:338-443; A:238-337; B:238-337 | CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (M3N2F)2 |
1H3V | A:338-443; B:338-443; A:238-337; B:238-337 | CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G2F)2,SG P212121 |
1H3W | M:338-443; M:238-337 | STRUCTURAL ANALYSIS OF HUMAN IGG-FC GLYCOFORMS REVEALS A CORRELATION BETWEEN GLYCOSYLATION AND STRUCTURAL INTEGRITY |
1H3X | A:338-443; B:338-443; A:238-337; B:239-337 | CRYSTAL STRUCTURE OF THE HUMAN IGG1 FC-FRAGMENT,GLYCOFORM (G0F)2 |
1H9V | A:87-171; A:1-86 | HUMAN FC-GAMMA-RECEPTOR IIA (FCGRIIA), MONOCLINIC |
1HCF | X:283-383; Y:283-383 | CRYSTAL STRUCTURE OF TRKB-D5 BOUND TO NEUROTROPHIN-4/5 |
1HDM | B:87-185; A:84-195 | HISTOCOMPATIBILITY ANTIGEN HLA-DM |
1HE7 | A:282-388 | HUMAN NERVE GROWTH FACTOR RECEPTOR TRKA |
1HEZ | A:108-211; B:1-121; D:1-121; D:122-222; B:122-222; C:108-211; A:1-107; C:1-107 | ANTIBODY-ANTIGEN COMPLEX |
1HHG | B:0-99; A:182-275; D:182-275; E:0-99 | THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2 |
1HHH | B:0-99; A:182-275 | THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2 |
1HHI | B:0-99; A:182-275; D:182-275; E:0-99 | THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2 |
1HHJ | B:0-99; A:182-275; D:182-275; E:0-99 | THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2 |
1HHK | B:0-99; A:182-275; D:182-275; E:0-99 | THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2 |
1HKF | A:5-112 | THE THREE DIMENSIONAL STRUCTURE OF NK CELL RECEPTOR NKP44, A TRIGGERING PARTNER IN NATURAL CYTOTOXICITY |
1HNF | A:4-103; A:104-182 | CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE HUMAN CELL ADHESION MOLECULE CD2 AT 2.5 ANGSTROMS RESOLUTION |
1HQR | A:82-180; B:293-390 | CRYSTAL STRUCTURE OF A SUPERANTIGEN BOUND TO THE HIGH-AFFINITY, ZINC-DEPENDENT SITE ON MHC CLASS II |
1HSA | B:1-99; E:1-99; A:182-276; D:182-276 | THE THREE-DIMENSIONAL STRUCTURE OF HLA-B27 AT 2.1 ANGSTROMS RESOLUTION SUGGESTS A GENERAL MECHANISM FOR TIGHT PEPTIDE BINDING TO MHC |
1HSB | B:1-99; A:182-270 | DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE |
1HWG | B:132-232; C:132-232; B:32-131; C:32-131 | 1:2 COMPLEX OF HUMAN GROWTH HORMONE WITH ITS SOLUBLE BINDING PROTEIN |
1HWH | B:132-232; B:32-131 | 1:1 COMPLEX OF HUMAN GROWTH HORMONE MUTANT G120R WITH ITS SOLUBLE BINDING PROTEIN |
1HXM | B:126-230; D:126-230; F:126-230; H:126-230; A:1-121; C:1-121; E:1-121; G:1-121; B:1-125; D:1-125; F:1-125; H:1-125; A:122-206; C:122-206; E:122-206; G:122-206 | CRYSTAL STRUCTURE OF A HUMAN VGAMMA9/VDELTA2 T CELL RECEPTOR |
1HXY | A:82-181; B:93-190 | CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN H IN COMPLEX WITH HUMAN MHC CLASS II |
1HYR | C:181-273 | CRYSTAL STRUCTURE OF HUMAN MICA IN COMPLEX WITH NATURAL KILLER CELL RECEPTOR NKG2D |
1HZH | L:108-211; L:1-107; M:1-108; K:105-230; H:361-474; K:361-473; K:1-104; H:250-360; K:250-360; H:129-236; H:24-128; M:109-211 | CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROAD AND POTENT ACTIVITY AGAINST PRIMARY HIV-1 ISOLATES: A TEMPLATE FOR HIV VACCINE DESIGN |
1I1F | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y |
1I1R | A:202-302; A:102-201; A:2-101 | CRYSTAL STRUCTURE OF A CYTOKINE/RECEPTOR COMPLEX |
1I1Y | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y |
1I4F | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4-PEPTIDE COMPLEX |
1I7R | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1058 |
1I7T | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-5V |
1I7U | B:0-99; E:0-99; A:182-270; D:182-270 | CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-6V |
1I85 | D:3-120; C:3-120; B:1-109; A:0-109 | CRYSTAL STRUCTURE OF THE CTLA-4/B7-2 COMPLEX |
1I8L | C:3-120; D:3-120; A:1-105; B:1-105; A:106-199; B:106-199 | HUMAN B7-1/CTLA-4 CO-STIMULATORY COMPLEX |
1I9R | L:113-215; L:1-112; M:1-112; Y:1-112; H:113-219; K:113-219; X:113-219; H:1-112; K:1-112; X:1-112; M:113-215; Y:113-215 | STRUCTURE OF CD40L IN COMPLEX WITH THE FAB FRAGMENT OF HUMANIZED 5C8 ANTIBODY |
1IAM | A:84-185; A:1-83 | STRUCTURE OF THE TWO AMINO-TERMINAL DOMAINS OF HUMAN INTERCELLULAR ADHESION MOLECULE-1, ICAM-1 |
1IAR | B:1-96; B:97-197 | INTERLEUKIN-4 / RECEPTOR ALPHA CHAIN COMPLEX |
1IC1 | A:84-190; B:84-190; A:1-83; B:1-83 | THE CRYSTAL STRUCTURE FOR THE N-TERMINAL TWO DOMAINS OF ICAM-1 |
1IGM | L:1-115; H:1-129 | THREE DIMENSIONAL STRUCTURE OF AN FV FROM A HUMAN IGM IMMUNOGLOBULIN |
1II4 | E:150-250; F:150-250; G:150-250; H:150-250; E:251-357; F:251-357; G:251-357; H:251-357 | CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 |
1IIL | E:150-250; F:150-250; G:150-250; H:150-250; G:251-357; H:251-357; E:251-357; F:251-357 | CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 |
1IJ9 | A:90-196; A:1-89 | HIGHLY HYDRATED HUMAN VCAM-1 FRAGMENT |
1IM3 | B:0-99; A:182-270; E:182-270; I:182-270; M:182-270; F:0-99; J:0-99; N:0-99 | CRYSTAL STRUCTURE OF THE HUMAN CYTOMEGALOVIRUS PROTEIN US2 BOUND TO THE MHC CLASS I MOLECULE HLA-A2/TAX |
1IM9 | B:0-99; A:182-272; E:182-272; D:103-200; D:6-102; F:0-99 | CRYSTAL STRUCTURE OF THE HUMAN NATURAL KILLER CELL INHIBITORY RECEPTOR KIR2DL1 BOUND TO ITS MHC LIGAND HLA-CW4 |
1IQD | A:110-211; A:2-109; B:115-210; B:1-114 | HUMAN FACTOR VIII C2 DOMAIN COMPLEXED TO HUMAN MONOCLONAL BO2C11 FAB. |
1IRA | Y:95-200; Y:201-311; Y:3-94 | COMPLEX OF THE INTERLEUKIN-1 RECEPTOR WITH THE INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL1RA) |
1ITB | B:98-203; B:204-315; B:6-97 | TYPE-1 INTERLEUKIN-1 RECEPTOR COMPLEXED WITH INTERLEUKIN-1 BETA |
1J7V | R:104-206; R:2-103 | HUMAN IL-10 / IL-10R1 COMPLEX |
1J86 | A:4-84; B:4-84; A:85-174; B:85-173 | HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), MONOCLINIC CRYSTAL FORM 2 |
1J87 | A:4-84; A:85-171 | HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), HEXAGONAL CRYSTAL FORM 1 |
1J88 | A:4-84; B:4-84; C:4-84; D:4-84; E:4-84; A:85-171; B:85-171; C:85-171; D:85-171; E:85-171 | HUMAN HIGH AFFINITY FC RECEPTOR FC(EPSILON)RI(ALPHA), TETRAGONAL CRYSTAL FORM 1 |
1J8H | E:3-118; D:117-202; A:82-181; E:119-246; B:92-190; D:1-116 | CRYSTAL STRUCTURE OF A COMPLEX OF A HUMAN ALPHA/BETA-T CELL RECEPTOR, INFLUENZA HA ANTIGEN PEPTIDE, AND MHC CLASS II MOLECULE, HLA-DR4 |
1J8K | A:1-94 | NMR STRUCTURE OF THE FIBRONECTIN EDA DOMAIN, NMR, 20 STRUCTURES |
1J9C | T:3-105; T:106-210 | CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX |
1JE6 | A:184-272 | STRUCTURE OF THE MHC CLASS I HOMOLOG MICB |
1JF1 | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH A DECAMERIC ALTERED PEPTIDE LIGAND FROM THE MART-1/MELAN-A |
1JGD | B:0-99; A:182-276 | HLA-B*2709 BOUND TO DECA-PEPTIDE S10R |
1JGE | B:0-99; A:182-276 | HLA-B*2705 BOUND TO NONA-PEPTIDE M9 |
1JHT | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH A NONAMERIC ALTERED PEPTIDE LIGAND (ALGIGILTV) FROM THE MART-1/MELAN-A. |
1JK8 | A:82-181; B:93-192 | CRYSTAL STRUCTURE OF A HUMAN INSULIN PEPTIDE-HLA-DQ8 COMPLEX |
1JNJ | A:0-99 | NMR SOLUTION STRUCTURE OF THE HUMAN BETA2-MICROGLOBULIN |
1JPS | L:109-211; H:118-216; T:5-105; T:106-210; H:1-117; L:1-108 | CRYSTAL STRUCTURE OF TISSUE FACTOR IN COMPLEX WITH HUMANIZED FAB D3H44 |
1JPT | L:109-211; H:118-216; H:1-117; L:1-108 | CRYSTAL STRUCTURE OF FAB D3H44 |
1JV5 | A:1-107; B:301-417 | ANTI-BLOOD GROUP A FV |
1JVK | A:2-112; B:2-112; A:113-213; B:113-213 | THREE-DIMENSIONAL STRUCTURE OF AN IMMUNOGLOBULIN LIGHT CHAIN DIMER ACTING AS A LETHAL AMYLOID PRECURSOR |
1JWM | A:82-181; B:93-190 | CRYSTAL STRUCTURE OF THE COMPLEX OF THE MHC CLASS II MOLECULE HLA-DR1(HA PEPTIDE 306-318) WITH THE SUPERANTIGEN SEC3 |
1JWS | A:82-181; B:93-190 | CRYSTAL STRUCTURE OF THE COMPLEX OF THE MHC CLASS II MOLECULE HLA-DR1 (HA PEPTIDE 306-318) WITH THE SUPERANTIGEN SEC3 VARIANT 3B1 |
1JWU | A:82-181; B:93-190 | CRYSTAL STRUCTURE OF THE COMPLEX OF THE MHC CLASS II MOLECULE HLA-DR1 (HA PEPTIDE 306-318) WITH THE SUPERANTIGEN SEC3 VARIANT 3B2 |
1K5N | B:0-99; A:182-276 | HLA-B*2709 BOUND TO NONA-PEPTIDE M9 |
1KF9 | B:332-432; E:1332-1432; F:1632-1732; C:632-731; E:1233-1331; B:233-331; F:1533-1631; C:533-631 | PHAGE DISPLAY DERIVED VARIANT OF HUMAN GROWTH HORMONE COMPLEXED WITH TWO COPIES OF THE EXTRACELLULAR DOMAIN OF ITS RECEPTOR |
1KFA | L:114-215; H:127-225; I:127-224; L:1-113; M:1-113; I:3-121; H:2-121; M:114-213 | CRYSTAL STRUCTURE OF FAB FRAGMENT COMPLEXED WITH GIBBERELLIN A4 |
1KG0 | A:82-181; B:93-190 | STRUCTURE OF THE EPSTEIN-BARR VIRUS GP42 PROTEIN BOUND TO THE MHC CLASS II RECEPTOR HLA-DR1 |
1KGC | D:2-116; E:3-118; D:117-206; E:119-247 | IMMUNE RECEPTOR |
1KLG | A:82-180; B:93-190 | CRYSTAL STRUCTURE OF HLA-DR1/TPI(23-37, THR28-->ILE MUTANT) COMPLEXED WITH STAPHYLOCOCCAL ENTEROTOXIN C3 VARIANT 3B2 (SEC3-3B2) |
1KLU | A:82-181; B:93-190 | CRYSTAL STRUCTURE OF HLA-DR1/TPI(23-37) COMPLEXED WITH STAPHYLOCOCCAL ENTEROTOXIN C3 VARIANT 3B2 (SEC3-3B2) |
1KPR | B:1-99; A:182-272; C:182-272; D:1-99 | THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E |
1KTL | B:1-99; A:182-272; C:182-272; D:1-99 | THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E |
1KV3 | A:588-685; B:588-685; C:588-685; D:588-685; E:588-685; F:588-685; A:15-147; B:15-147; C:15-147; D:15-147; E:15-147; F:15-147; A:471-587; B:471-587; C:471-587; D:471-587; E:471-587; F:471-587 | HUMAN TISSUE TRANSGLUTAMINASE IN GDP BOUND FORM |
1L6X | A:338-443; A:238-337 | FC FRAGMENT OF RITUXIMAB BOUND TO A MINIMIZED VERSION OF THE B-DOMAIN FROM PROTEIN A CALLED Z34C |
1L7I | L:109-211; H:114-213; H:1-113; L:1-108 | CRYSTAL STRUCTURE OF THE ANTI-ERBB2 FAB2C4 |
1L9M | A:595-691; B:595-691; A:480-594; B:478-594; A:1-142; B:1-142 | THREE-DIMENSIONAL STRUCTURE OF THE HUMAN TRANSGLUTAMINASE 3 ENZYME: BINDING OF CALCIUM IONS CHANGE STRUCTURE FOR ACTIVATION |
1L9N | A:595-691; B:595-691; A:481-594; B:481-594; A:1-142; B:1-142 | THREE-DIMENSIONAL STRUCTURE OF THE HUMAN TRANSGLUTAMINASE 3 ENZYME: BINDING OF CALCIUM IONS CHANGE STRUCTURE FOR ACTIVATION |
1LDS | A:0-96 | CRYSTAL STRUCTURE OF MONOMERIC HUMAN BETA-2-MICROGLOBULIN |
1LGV | A:2-112; B:2-112; A:113-213; B:113-213 | STRUCTURE OF A HUMAN BENCE-JONES DIMER CRYSTALLIZED IN U.S. SPACE SHUTTLE MISSION STS-95: 100K |
1LHZ | A:2-112; B:2-112; A:113-213; B:113-213 | STRUCTURE OF A HUMAN BENCE-JONES DIMER CRYSTALLIZED IN U.S. SPACE SHUTTLE MISSION STS-95: 293K |
1LIL | A:2-107; B:2-107; A:108-211; B:108-211 | BENCE JONES PROTEIN CLE, A LAMBDA III IMMUNOGLOBULIN LIGHT-CHAIN DIMER |
1LK3 | L:108-210; I:120-218; H:120-217; L:1-107; M:1-107; H:1-119; I:1-119; M:108-210 | ENGINEERED HUMAN INTERLEUKIN-10 MONOMER COMPLEXED TO 9D7 FAB FRAGMENT |
1LO5 | A:82-181; B:93-190 | CRYSTAL STRUCTURE OF THE D227A VARIANT OF STAPHYLOCOCCAL ENTEROTOXIN A IN COMPLEX WITH HUMAN MHC CLASS II |
1LP9 | B:0-99; A:182-270; H:182-270; I:0-99; F:3-117; M:3-117; E:117-198; L:117-198; F:118-245; M:118-245; E:1-116; L:1-116 | XENOREACTIVE COMPLEX AHIII 12.2 TCR BOUND TO P1049/HLA-A2.1 |
1LQS | R:104-206; S:104-206; R:2-103; S:2-103 | CRYSTAL STRUCTURE OF HUMAN CYTOMEGALOVIRUS IL-10 BOUND TO SOLUBLE HUMAN IL-10R1 |
1LVE | A:1-108 | STRUCTURE OF THE VARIABLE DOMAIN OF HUMAN IMMUNOGLOBULIN K-4 LIGHT CHAIN LEN |
1M05 | B:1-99; D:1-99; A:182-272; C:182-272 | HLA B8 IN COMPLEX WITH AN EPSTEIN BARR VIRUS DETERMINANT |
1M4K | A:103-200; A:8-102 | CRYSTAL STRUCTURE OF THE HUMAN NATURAL KILLER CELL ACTIVATOR RECEPTOR KIR2DS2 (CD158J) |
1M6O | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA B*4402 IN COMPLEX WITH HLA DPA*0201 PEPTIDE |
1MCC | A:1-111; B:1-111; A:112-212; B:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCD | A:1-111; B:1-111; B:112-216; A:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCE | B:2-111; A:1-111; A:112-212; B:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCF | A:1-111; B:1-111; A:112-212; B:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCH | A:1-111; B:1-111; A:112-212; B:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCI | A:1-111; B:1-111; A:112-212; B:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCJ | A:1-111; B:1-111; A:112-212; B:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCK | A:1-111; B:1-111; A:112-212; B:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCN | A:1-111; B:1-111; A:112-212; B:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCO | H:120-221; H:328-428; L:1-111; H:1-118; L:112-212; H:223-326 | THREE-DIMENSIONAL STRUCTURE OF A HUMAN IMMUNOGLOBULIN WITH A HINGE DELETION |
1MCQ | A:1-111; B:1-111; A:112-216; B:112-216 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCR | A:1-111; B:1-111; A:112-212; B:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCS | A:1-111; B:1-111; A:112-212; B:112-212 | PRINCIPLES AND PITFALLS IN DESIGNING SITE DIRECTED PEPTIDE LIGANDS |
1MCW | M:2-111; W:2-112; M:112-216; W:113-216 | THREE-DIMENSIONAL STRUCTURE OF A HYBRID LIGHT CHAIN DIMER. PROTEIN ENGINEERING OF A BINDING CAVITY |
1MHE | B:1-99; A:182-272; C:182-272; D:1-99 | THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E |
1MI5 | B:1-99; D:2-116; E:3-118; D:117-206; E:119-247; A:182-272 | THE CRYSTAL STRUCTURE OF LC13 TCR IN COMPLEX WITH HLAB8-EBV PEPTIDE COMPLEX |
1MQ8 | A:84-184; C:84-184; A:1-83; C:1-83 | CRYSTAL STRUCTURE OF ALPHAL I DOMAIN IN COMPLEX WITH ICAM-1 |
1N0X | L:108-211; L:1-107; M:1-107; K:110-230; H:110-228; H:1-109; K:1-109; M:108-211 | CRYSTAL STRUCTURE OF A BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY IN COMPLEX WITH A PEPTIDE MIMOTOPE |
1N26 | A:196-299; A:2-9,A:94-192; A:14-91 | CRYSTAL STRUCTURE OF THE EXTRA-CELLULAR DOMAINS OF HUMAN INTERLEUKIN-6 RECEPTOR ALPHA CHAIN |
1N2R | B:1-99; A:182-272 | A NATURAL SELECTED DIMORPHISM IN HLA B*44 ALTERS SELF, PEPTIDE REPORTOIRE AND T CELL RECOGNITION. |
1N6U | A:1-106; A:107-212 | NMR STRUCTURE OF THE INTERFERON-BINDING ECTODOMAIN OF THE HUMAN INTERFERON RECEPTOR |
1N6V | A:1-106; A:107-212 | AVERAGE STRUCTURE OF THE INTERFERON-BINDING ECTODOMAIN OF THE HUMAN TYPE I INTERFERON RECEPTOR |
1N8Z | A:109-211; B:121-220; B:1-120; A:1-108 | CRYSTAL STRUCTURE OF EXTRACELLULAR DOMAIN OF HUMAN HER2 COMPLEXED WITH HERCEPTIN FAB |
1NBQ | A:129-233; B:129-233; A:25-128; B:26-128 | CRYSTAL STRUCTURE OF HUMAN JUNCTIONAL ADHESION MOLECULE TYPE 1 |
1NCN | A:0-109; B:0-109 | THE RECEPTOR-BINDING DOMAIN OF HUMAN B7-2 |
1NCT | A:-6-91 | TITIN MODULE M5, N-TERMINALLY EXTENDED, NMR |
1NCU | A:-6-91 | TITIN MODULE M5, N-TERMINALLY EXTENDED, NMR |
1NFI | A:190-292; C:190-292; B:249-355; D:249-355 | I-KAPPA-B-ALPHA/NF-KAPPA-B COMPLEX |
1NKO | A:21-147 | ENERGETIC AND STRUCTURAL BASIS OF SIALYLATED OLIGOSACCHARIDE RECOGNITION BY THE NATURAL KILLER CELL INHIBITORY RECEPTOR P75/AIRM1 OR SIGLEC-7 |
1NKR | A:103-200; A:6-102 | INHIBITORY RECEPTOR (P58-CL42) FOR HUMAN NATURAL KILLER CELLS |
1NL0 | H:114-214; L:1-108; L:109-209; H:1-113 | CRYSTAL STRUCTURE OF HUMAN FACTOR IX GLA DOMAIN IN COMPLEX OF AN INHIBITORY ANTIBODY, 10C12 |
1NUD | A:595-691; B:595-691; A:481-594; B:481-594; A:1-142; B:1-142 | ROLE OF CALCIUM IONS IN THE ACTIVATION AND ACTIVITY OF THE TRANSGLUTAMINASE 3 ENZYME (3 CALCIUMS, ACTIVE FORM) |
1NUF | A:595-691; A:480-594; A:1-142 | ROLE OF CALCIUM IONS IN THE ACTIVATION AND ACTIVITY OF THE TRANSGLUTAMINASE 3 ENZYME |
1NUG | A:595-691; B:595-691; A:480-594; B:478-594; A:1-142; B:1-142 | ROLE OF CALCIUM IONS IN THE ACTIVATION AND ACTIVITY OF THE TRANSGLUTAMINASE 3 ENZYME (2 CALCIUMS, 1 MG, INACTIVE FORM) |
1NUN | B:151-250; B:251-355 | CRYSTAL STRUCTURE ANALYSIS OF THE FGF10-FGFR2B COMPLEX |
1O0V | B:436-545; A:436-545; A:329-435; B:329-435; A:228-328; B:228-328 | THE CRYSTAL STRUCTURE OF IGE FC REVEALS AN ASYMMETRICALLY BENT CONFORMATION |
1O5D | T:6-205 | DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA) |
1O7S | A:24-144 | HIGH RESOLUTION STRUCTURE OF SIGLEC-7 |
1O7V | A:18-144 | HIGH RESOLUTION STRUCTURE OF SIGLEC-7 |
1OF2 | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408) |
1OGA | B:0-99; D:3-111; E:5-115; D:112-201; E:116-244; A:182-270 | A STRUCTURAL BASIS FOR IMMUNODOMINANT HUMAN T-CELL RECEPTOR RECOGNITION. |
1OGT | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408) |
1OHQ | B:1-119; A:1-120 | CRYSTAL STRUCTURE OF HEL4, A SOLUBLE HUMAN VH ANTIBODY DOMAIN RESISTANT TO AGGREGATION |
1OL0 | A:1-121; B:1-121 | CRYSTAL STRUCTURE OF A CAMELISED HUMAN VH |
1OLZ | A:539-628; B:539-628 | THE LIGAND-BINDING FACE OF THE SEMAPHORINS REVEALED BY THE HIGH RESOLUTION CRYSTAL STRUCTURE OF SEMA4D |
1OM3 | M:109-211; H:114-227; K:114-226; H:1-113; K:1-113; L:108-211; L:2-107; M:2-108 | FAB 2G12 UNLIGANDED |
1ONQ | B:1-99; D:1-99; A:183-278; C:183-278 | CRYSTAL STRUCTURE OF CD1A IN COMPLEX WITH A SULFATIDE |
1OP3 | L:109-211; H:114-222; M:114-222; H:1-113; M:1-113; K:108-211; K:2-107; L:2-108 | CRYSTAL STRUCTURE OF FAB 2G12 BOUND TO MAN1->2MAN |
1OP5 | K:109-208; H:114-226; M:114-226; H:1-113; M:1-113; L:108-211; L:2-107; K:2-108 | CRYSTAL STRUCTURE OF FAB 2G12 BOUND TO MAN9GLCNAC2 |
1OPG | L:108-211; H:126-223; H:1-125; L:1-107 | OPG2 FAB FRAGMENT |
1OQO | A:338-443; B:338-443; A:238-337; B:238-337 | COMPLEX BETWEEN G0 VERSION OF AN FC BOUND TO A MINIMIZED VERSION OF PROTEIN A CALLED MINI-Z |
1OQX | A:338-443; B:338-443; A:238-337; B:238-337 | G-2 GLYCOVARIANT OF HUMAN IGG FC BOUND TO MINIMIZED VERSION OF PROTEIN A CALLED Z34C |
1OVZ | A:100-198; B:100-192; B:5-99; A:6-99 | CRYSTAL STRUCTURE OF HUMAN FCARI |
1OW0 | C:100-195; D:100-195; C:6-99; D:6-99; A:342-450; B:342-450; A:242-341; B:242-341 | CRYSTAL STRUCTURE OF HUMAN FCARI BOUND TO IGA1-FC |
1OWW | A:1-93 | SOLUTION STRUCTURE OF THE FIRST TYPE III MODULE OF HUMAN FIBRONECTIN DETERMINED BY 1H, 15N NMR SPECTROSCOPY |
1P53 | A:185-282; B:185-282; A:368-450; B:368-450; A:283-367; B:283-367 | THE CRYSTAL STRUCTURE OF ICAM-1 D3-D5 FRAGMENT |
1P6F | A:99-191; A:4-98 | STRUCTURE OF THE HUMAN NATURAL CYTOTOXICITY RECEPTOR NKP46 |
1P7Q | B:1-99; A:182-270; D:97-198; D:4-96 | CRYSTAL STRUCTURE OF HLA-A2 BOUND TO LIR-1, A HOST AND VIRAL MHC RECEPTOR |
1P9M | A:202-299; A:102-201; C:196-296; C:96-195; A:2-101 | CRYSTAL STRUCTURE OF THE HEXAMERIC HUMAN IL-6/IL-6 ALPHA RECEPTOR/GP130 COMPLEX |
1PD6 | A:208-301 | THE NMR STRUCTURE OF DOMAIN C2 OF HUMAN CARDIAC MYOSIN BINDING PROTEIN C |
1PEW | A:1-108; B:1-108 | HIGH RESOLUTION CRYSTAL STRUCTURE OF JTO2, A MUTANT OF THE NON-AMYLOIDOGENIC LAMBA6 LIGHT CHAIN, JTO |
1PGR | B:1-108; F:1-108; D:3-108; H:3-108; F:109-213; B:109-213; D:109-213; H:109-213 | 2:2 COMPLEX OF G-CSF WITH ITS RECEPTOR |
1PVH | A:201-301; C:201-301; A:101-200; C:101-200 | CRYSTAL STRUCTURE OF LEUKEMIA INHIBITORY FACTOR IN COMPLEX WITH GP130 |
1PW3 | A:1-108; B:1-108 | CRYSTAL STRUCTURE OF JTOR68S |
1PY4 | A:0-97; B:1-97; D:1-97; C:2-97 | BETA2 MICROGLOBULIN MUTANT H31Y DISPLAYS HINTS FOR AMYLOID FORMATIONS |
1PYW | A:82-181; B:93-190 | HUMAN CLASS II MHC PROTEIN HLA-DR1 BOUND TO A DESIGNED PEPTIDE RELATED TO INFLUENZA VIRUS HEMAGGLUTININ, FVKQNA(MAA)AL, IN COMPLEX WITH STAPHYLOCOCCAL ENTEROTOXIN C3 VARIANT 3B2 (SEC3-3B2) |
1Q1J | H:114-223; I:114-223; L:2-107; M:2-107; L:108-211; M:108-211; H:1-113; I:1-113 | CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 FAB 447-52D IN COMPLEX WITH V3 PEPTIDE |
1Q38 | A:1-89 | ANASTELLIN |
1Q8M | A:16-136; B:16-136; C:16-136; D:16-136 | CRYSTAL STRUCTURE OF THE HUMAN MYELOID CELL ACTIVATING RECEPTOR TREM-1 |
1Q94 | B:0-99; E:0-99; A:182-275; D:182-275 | STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE |
1QA9 | B:1-95; D:1-95; A:4-105; C:4-105 | STRUCTURE OF A HETEROPHILIC ADHESION COMPLEX BETWEEN THE HUMAN CD2 AND CD58(LFA-3) COUNTER-RECEPTORS |
1QAC | A:1-108; B:301-408 | CHANGE IN DIMERIZATION MODE BY REMOVAL OF A SINGLE UNSATISFIED POLAR RESIDUE |
1QEW | B:0-99; A:182-270 | HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) COMPLEX WITH A NONAMERIC PEPTIDE FROM MELANOMA-ASSOCIATED ANTIGEN 3 (RESIDUES 271-279) |
1QFW | H:3-117; L:1-114; M:201-308; I:201-321 | TERNARY COMPLEX OF HUMAN CHORIONIC GONADOTROPIN WITH FV ANTI ALPHA SUBUNIT AND FV ANTI BETA SUBUNIT |
1QG3 | A:1217-1320; B:1217-1319; A:1126-1216; B:1127-1216 | CRYSTAL STRUCTURE OF A TANDEM PAIR OF FIBRONECTIN TYPE III DOMAINS FROM THE CYTOPLASMIC TAIL OF INTEGRIN ALPHA6 BETA4 |
1QLR | A:109-211; A:1-108; C:1-108; B:1-120; D:1-120; D:121-223; B:121-222; C:109-211 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF A HUMAN MONOCLONAL IGM COLD AGGLUTININ |
1QP1 | A:1-107; B:1-107; C:1-107 | KAPPA VARIABLE LIGHT CHAIN |
1QQD | B:0-98; A:182-272 | CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER CELL INHIBITORY RECEPTOR |
1QR1 | B:0-99; A:182-270; D:182-270; E:0-99 | POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE |
1QRK | A:518-630; B:517-630; A:631-724; B:631-724; A:9-192; B:10-192 | HUMAN FACTOR XIII WITH STRONTIUM BOUND IN THE ION SITE |
1QRN | B:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116 | CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A |
1QSE | B:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116 | STRUCTURE OF HUMAN A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R |
1QSF | B:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116 | STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A |
1QSV | A:129-229 | THE VEGF-BINDING DOMAIN OF FLT-1, 20 NMR STRUCTURES |
1QSZ | A:129-229 | THE VEGF-BINDING DOMAIN OF FLT-1 (MINIMIZED MEAN) |
1QTY | T:132-225; U:132-225; X:132-225; Y:132-225 | VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH DOMAIN 2 OF THE FLT-1 RECEPTOR |
1QVO | B:0-99; E:0-99; A:182-275; D:182-275 | STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE |
1R5I | A:82-181; E:82-181; B:93-190; F:93-190 | CRYSTAL STRUCTURE OF THE MAM-MHC COMPLEX |
1REI | A:1-107; B:1-107 | THE MOLECULAR STRUCTURE OF A DIMER COMPOSED OF THE VARIABLE PORTIONS OF THE BENCE-JONES PROTEIN REI REFINED AT 2.0 ANGSTROMS RESOLUTION |
1RHF | A:7-97; B:7-97; A:98-182; B:98-182 | CRYSTAL STRUCTURE OF HUMAN TYRO3-D1D2 |
1RHH | A:108-210; A:1-107; C:1-107; B:114-213; D:114-213; D:4-113; B:3-113; C:108-210 | CRYSTAL STRUCTURE OF THE BROADLY HIV-1 NEUTRALIZING FAB X5 AT 1.90 ANGSTROM RESOLUTION |
1RPQ | D:4-84; C:4-84; A:4-84; B:4-84; A:85-171; B:85-171; C:85-171; D:85-171 | HIGH AFFINITY IGE RECEPTOR (ALPHA CHAIN) COMPLEXED WITH TIGHT-BINDING E131 'ZETA' PEPTIDE FROM PHAGE DISPLAY |
1RSF | A:19-144 | NMR STRUCTURE OF MONOMERIC CAR D1 DOMAIN |
1RV6 | X:133-224; Y:133-224 | CRYSTAL STRUCTURE OF PLGF IN COMPLEX WITH DOMAIN 2 OF VEGFR1 |
1RY7 | B:150-247; B:248-362 | CRYSTAL STRUCTURE OF THE 3 IG FORM OF FGFR3C IN COMPLEX WITH FGF1 |
1RZ7 | L:108-211; H:110-213; H:1-109; L:2-107 | CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 48D |
1RZ8 | A:109-211; A:1-108; C:1-108; B:114-213; D:114-213; B:1-113; D:1-113; C:109-211 | CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 17B |
1RZF | H:111-214; L:3-108; H:2-110; L:109-209 | CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY E51 |
1RZG | B:110-211; A:110-214; C:110-213; C:2-109; A:1-109; D:110-211; B:1-108; D:1-108 | CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120 REACTIVE ANTIBODY 412D |
1RZI | A:108-211; F:114-214; B:114-213; D:114-213; H:114-213; J:114-213; L:114-213; N:114-213; P:114-213; L:1-113; B:1-113; D:1-113; F:1-113; H:1-113; J:1-113; N:1-113; P:1-113; C:108-211; E:108-211; G:108-211; I:108-211; K:108-211; M:108-211; O:108-211; A:2-107; E:2-107; G:2-107; I:2-107; K:2-107; M:2-107; O:2-107; C:1-107 | CRYSTAL STRUCTURE OF HUMAN ANTI-HIV-1 GP120-REACTIVE ANTIBODY 47E FAB |
1S78 | C:109-211; D:114-213; F:114-213; D:1-113; F:1-113; E:109-211; C:1-108; E:1-108 | INSIGHTS INTO ERBB SIGNALING FROM THE STRUCTURE OF THE ERBB2-PERTUZUMAB COMPLEX |
1S8D | B:1-99; A:182-270 | STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-3A |
1S9V | A:82-180; D:82-178; B:93-190; E:93-190 | CRYSTAL STRUCTURE OF HLA-DQ2 COMPLEXED WITH DEAMIDATED GLIADIN PEPTIDE |
1S9W | B:0-99; A:182-270 | CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE, SLLMWITQC, IN COMPLEX WITH HLA-A2 |
1S9X | B:0-99; A:182-270 | CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE ANALOGUE, SLLMWITQA, IN COMPLEX WITH HLA-A2 |
1S9Y | B:0-99; A:182-270 | CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE ANALOGUE, SLLMWITQS, IN COMPLEX WITH HLA-A2 |
1SEB | A:82-181; E:82-181; B:93-192; F:93-192 | COMPLEX OF THE HUMAN MHC CLASS II GLYCOPROTEIN HLA-DR1 AND THE BACTERIAL SUPERANTIGEN SEB |
1SJE | A:82-181; B:93-190 | HLA-DR1 COMPLEXED WITH A 16 RESIDUE HIV CAPSID PEPTIDE BOUND IN A HAIRPIN CONFORMATION |
1SJH | A:82-181; B:93-190 | HLA-DR1 COMPLEXED WITH A 13 RESIDUE HIV CAPSID PEPTIDE |
1SMO | B:26-135; A:21-133 | CRYSTAL STRUCTURE OF HUMAN TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 (TREM-1) AT 1.47 . |
1SYS | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA, B*4403, AND PEPTIDE EEPTVIKKY |
1SYV | B:1-99; A:182-272 | HLA-B*4405 COMPLEXED TO THE DOMINANT SELF LIGAND EEFGRAYGF |
1T04 | A:108-211; B:2-117; D:2-117; B:118-217; D:118-217; C:108-211; A:1-107; C:1-107 | THREE DIMENSIONAL STRUCTURE OF A HUMANIZED ANTI-IFN-GAMMA FAB IN C2 SPACE GROUP |
1T0P | B:1-86 | STRUCTURAL BASIS OF ICAM RECOGNITION BY INTEGRIN ALPAHLBETA2 REVEALED IN THE COMPLEX STRUCTURE OF BINDING DOMAINS OF ICAM-3 AND ALPHALBETA2 AT 1.65 A |
1T1W | B:1-99; A:182-270 | STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-3F6I8V |
1T1X | B:1-99; A:182-270 | STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-4L |
1T1Y | B:1-99; A:182-270 | STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-5V |
1T1Z | B:1-99; A:182-270 | STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-6A |
1T20 | B:1-99; A:182-270 | STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-6I |
1T21 | B:1-99; A:182-270 | STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9, MONOCLINIC CRYSTAL |
1T22 | B:1-99; A:182-270 | STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDE VARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9, ORTHORHOMBIC CRYSTAL |
1T2J | A:1-113 | CRYSTAL STRUCTURE OF A HUMAN VH DOMAIN |
1T3F | A:108-211; B:2-117; B:118-217; A:1-107 | THREE DIMENSIONAL STRUCTURE OF A HUMANIZED ANTI-IFN-GAMMA FAB (HUZAF) IN P21 21 21 SPACE GROUP |
1T5W | A:82-181; D:82-181; B:93-190; E:93-190 | HLA-DR1 IN COMPLEX WITH A SYNTHETIC PEPTIDE (AAYSDQATPLLLSPR) |
1T5X | A:82-181; B:93-190 | HLA-DR1 IN COMPLEX WITH A SYNTHETIC PEPTIDE (AAYSDQATPLLLSPR) AND THE SUPERANTIGEN SEC3-3B2 |
1T7V | A:184-273 | ZN-ALPHA-2-GLYCOPROTEIN; BACULO-ZAG PEG 200 |
1T7W | A:184-273 | ZN-ALPHA-2-GLYCOPROTEIN; CHO-ZAG PEG 400 |
1T7X | A:184-273 | ZN-ALPHA-2-GLYCOPROTEIN; REFOLDED CHO-ZAG PEG 400 |
1T7Y | A:184-273 | ZN-ALPHA-2-GLYCOPROTEIN; BACULO-ZAG PEG 200, NO GLYCEROL |
1T7Z | A:184-273 | ZN-ALPHA-2-GLYCOPROTEIN; BACULO-ZAG NO PEG, NO GLYCEROL |
1T80 | A:184-273 | ZN-ALPHA-2-GLYCOPROTEIN; CHO-ZAG PEG 200 |
1T83 | A:338-443; B:338-443; A:238-337; B:238-337; C:90-171; C:5-89 | CRYSTAL STRUCTURE OF A HUMAN TYPE III FC GAMMA RECEPTOR IN COMPLEX WITH AN FC FRAGMENT OF IGG1 (ORTHORHOMBIC) |
1T89 | A:338-443; B:338-443; A:238-337; B:238-337; C:90-171; C:5-89 | CRYSTAL STRUCTURE OF A HUMAN TYPE III FC GAMMA RECEPTOR IN COMPLEX WITH AN FC FRAGMENT OF IGG1 (HEXAGONAL) |
1TEN | A:802-891 | STRUCTURE OF A FIBRONECTIN TYPE III DOMAIN FROM TENASCIN PHASED BY MAD ANALYSIS OF THE SELENOMETHIONYL PROTEIN |
1TFH | A:5-105; B:5-105; A:106-210; B:106-205 | EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR |
1TIT | A:1-89 | TITIN, IG REPEAT 27, NMR, MINIMIZED AVERAGE STRUCTURE |
1TIU | A:1-89 | TITIN, IG REPEAT 27, NMR, 24 STRUCTURES |
1TJG | L:108-211; H:114-213; H:1-113; L:1-107 | CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY 2F5 IN COMPLEX WITH A GP41 7MER EPITOPE |
1TJH | L:108-211; H:114-213; H:1-113; L:1-107 | CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY 2F5 IN COMPLEX WITH A GP41 11MER EPITOPE |
1TJI | L:108-211; H:114-213; H:1-113; L:1-107 | CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY 2F5 IN COMPLEX WITH A GP41 17MER EPITOPE |
1TMC | B:1-99 | THE THREE-DIMENSIONAL STRUCTURE OF A CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE MISSING THE ALPHA3 DOMAIN OF THE HEAVY CHAIN |
1TNM | A:1-91 | TERTIARY STRUCTURE OF AN IMMUNOGLOBULIN-LIKE DOMAIN FROM THE GIANT MUSCLE PROTEIN TITIN: A NEW MEMBER OF THE I SET |
1TNN | A:1-91 | TERTIARY STRUCTURE OF AN IMMUNOGLOBULIN-LIKE DOMAIN FROM THE GIANT MUSCLE PROTEIN TITIN: A NEW MEMBER OF THE I SET |
1TTF | A:1-94 | THE THREE-DIMENSIONAL STRUCTURE OF THE TENTH TYPE III MODULE OF FIBRONECTIN: AN INSIGHT INTO RGD-MEDIATED INTERACTIONS |
1TTG | A:1-94 | THE THREE-DIMENSIONAL STRUCTURE OF THE TENTH TYPE III MODULE OF FIBRONECTIN: AN INSIGHT INTO RGD-MEDIATED INTERACTIONS |
1TVB | B:0-99; E:0-99; A:182-270; D:182-270 | CRYSTAL STRUCTURE OF MELANOMA ANTIGEN GP100(209-217) BOUND TO HUMAN CLASS I MHC HLA-A2 |
1TVD | A:1-116; B:1-116 | VARIABLE DOMAIN OF T CELL RECEPTOR DELTA CHAIN |
1TVH | B:0-99; E:0-99; A:182-270; D:182-270 | CRYSTAL STRUCTURE OF MODIFIED MELANOMA ANTIGEN GP100(209-T2M) BOUND TO HUMAN CLASS I MHC HLA-A2 |
1TZG | L:109-211; L:1-108; M:1-108; I:110-228; H:110-232; H:1-109; I:1-109; M:109-211 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A 13-RESIDUE PEPTIDE CONTAINING THE 4E10 EPITOPE ON GP41 |
1TZH | A:109-211; B:114-213; H:114-213; B:1-113; H:1-113; L:109-211; A:1-108; L:1-108 | CRYSTAL STRUCTURE OF THE FAB YADS1 COMPLEXED WITH H-VEGF |
1U2H | A:17-112 | X-RAY STRUCTURE OF THE N-TERMINALLY TRUNCATED HUMAN APEP-1 |
1U6A | L:109-211; L:1-108; H:114-212; H:2-113 | CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV FAB F105 |
1U8H | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ALDKWAS |
1U8I | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWAN |
1U8J | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWAG |
1U8K | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE LELDKWASL |
1U8L | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE DLDRWAS |
1U8M | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKYAS |
1U8N | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKFAS |
1U8O | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKHAS |
1U8P | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ECDKWCS |
1U8Q | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELEKWAS |
1U91 | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ANALOG ENDKW-[DAP]-S (CYCLIC) |
1U92 | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ANALOG E-[DAP]-DKWQS (CYCLIC) |
1U93 | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ANALOG EQDKW-[DAP]-S (CYCLIC) |
1U95 | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDHWAS |
1UAD | C:4-95; D:4-95 | CRYSTAL STRUCTURE OF THE RALA-GPPNHP-SEC5 RAL-BINDING DOMAIN COMPLEX |
1UC6 | A:1-109 | SOLUTION STRUCTURE OF THE CARBOXYL TERMINAL DOMAIN OF THE CILIARY NEUROTROPHIC FACTOR RECEPTOR |
1UCT | A:101-195; A:6-100 | CRYSTAL STRUCTURE OF THE EXTRACELLULAR FRAGMENT OF FC ALPHA RECEPTOR I (CD89) |
1UEM | A:1-117 | SOLUTION STRUCTURE OF THE FIRST FIBRONECTIN TYPE III DOMAIN OF HUMAN KIAA1568 PROTEIN |
1UEN | A:1-125 | SOLUTION STRUCTURE OF THE THIRD FIBRONECTIN III DOMAIN OF HUMAN KIAA0343 PROTEIN |
1UEY | A:1-127 | SOLUTION STRUCTURE OF THE FIRST FIBRONECTIN TYPE III DOMAIN OF HUMAN KIAA0343 PROTEIN |
1UFU | A:97-195; A:2-96 | CRYSTAL STRUCTURE OF LIGAND BINDING DOMAIN OF IMMUNOGLOBULIN-LIKE TRANSCRIPT 2 (ILT2; LIR-1) |
1UGN | A:97-198; A:2-96 | CRYSTAL STRUCTURE OF LIR1.02, ONE OF THE ALLELES OF LIR1 |
1UJ3 | A:109-211; B:418-517; C:606-705; C:706-810; B:301-417; A:1-108 | CRYSTAL STRUCTURE OF A HUMANIZED FAB FRAGMENT OF ANTI-TISSUE-FACTOR ANTIBODY IN COMPLEX WITH TISSUE FACTOR |
1UJT | A:1-120 | SOLUTION STRUCTURE OF THE SECOND FIBRONECTIN TYPE III DOMAIN OF HUMAN KIAA1568 PROTEIN |
1UQS | B:0-99; A:183-278 | THE CRYSTAL STRUCTURE OF HUMAN CD1B WITH A BOUND BACTERIAL GLYCOLIPID |
1UVQ | A:85-183; B:93-191 | CRYSTAL STRUCTURE OF HLA-DQ0602 IN COMPLEX WITH A HYPOCRETIN PEPTIDE |
1UXS | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTEIN-BARR VIRUS |
1UXW | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS |
1V05 | A:-3-2725 | DIMERIZATION OF HUMAN FILAMIN C: CRYSTAL STRUCTURE OF THE DOMAIN 24 |
1V5J | A:1-108 | SOLUTION STRUCTURE OF RSGI RUH-008, FN3 DOMAIN IN HUMAN CDNA |
1VCA | A:90-199; B:90-199; A:1-89; B:1-89 | CRYSTAL STRUCTURE OF AN INTEGRIN-BINDING FRAGMENT OF VASCULAR CELL ADHESION MOLECULE-1 AT 1.8 ANGSTROMS RESOLUTION |
1VDG | A:97-197; B:97-197; B:2-96; A:2-96 | CRYSTAL STRUCTURE OF LIR1.01, ONE OF THE ALLELES OF LIR1 |
1VGE | L:109-211; H:123-222; H:2-122; L:1-108 | TR1.9 FAB FRAGMENT OF A HUMAN IGG1 KAPPA AUTOANTIBODY |
1VHP | A:1-117 | VH-P8, NMR |
1VSC | A:90-196; B:90-196; A:1-89; B:1-89 | VCAM-1 |
1W0V | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1 |
1W0W | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF-RESPONSE FACTOR 1 |
1W0Y | T:6-105; T:106-210 | TF7A_3771 COMPLEX |
1W2K | T:6-105; T:106-210 | TF7A_4380 COMPLEX |
1W72 | B:0-99; H:114-228; I:114-228; E:0-99; L:1-107; M:1-107; L:108-211; M:108-211; H:1-113; I:1-113; A:182-274; D:182-274 | CRYSTAL STRUCTURE OF HLA-A1:MAGE-A1 IN COMPLEX WITH FAB-HYB3 |
1WAA | C:-3-89; D:-3-89; A:-2-89; B:1-89; F:-3-89; E:-3-88 | IG27 PROTEIN DOMAIN |
1WIO | A:1-98; B:1-98; A:181-291; B:181-291; A:99-180; B:99-180; A:292-363; B:292-363 | STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, TETRAGONAL CRYSTAL FORM |
1WIP | A:1-98; B:1-98; A:181-291; B:181-291; A:99-180; B:99-180; A:292-363; B:292-363 | STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, MONOCLINIC CRYSTAL FORM |
1WQV | T:6-105; T:106-210 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D-THR-MET-P-AMINOBENZAMIDINE |
1WSS | T:6-105; T:106-210 | HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4 |
1WT5 | C:1-111; D:1-111; A:1-115; B:1-115 | THE CRYSTAL STRUCTURE OF A HUMANIZED ANTIBODY FV 528 |
1WTG | T:6-105; T:106-210 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE |
1WTL | A:1-108; B:1-108 | COMPARISON OF CRYSTAL STRUCTURES OF TWO HOMOLOGOUS PROTEINS: STRUCTURAL ORIGIN OF ALTERED DOMAIN INTERACTIONS IN IMMUNOGLOBULIN LIGHT CHAIN DIMERS |
1WUN | T:6-105; T:106-210 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE |
1WV7 | T:6-105; T:106-210 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE |
1WVZ | A:9-104 | SOLUTION STRUCTURE OF THE D2 DOMAIN OF THE FIBROBLAST GROWTH FACTOR |
1WWA | X:282-386; Y:278-382 | NGF BINDING DOMAIN OF HUMAN TRKA RECEPTOR |
1WWB | X:283-385 | LIGAND BINDING DOMAIN OF HUMAN TRKB RECEPTOR |
1WWC | A:300-404 | NT3 BINDING DOMAIN OF HUMAN TRKC RECEPTOR |
1WWW | X:282-382; Y:282-382 | NGF IN COMPLEX WITH DOMAIN 5 OF THE TRKA RECEPTOR |
1X7Q | B:1-99; A:182-275 | CRYSTAL STRUCTURE OF HLA-A*1101 WITH SARS NUCLEOCAPSID PEPTIDE |
1X9Q | A:14-124; A:149-268 | 4M5.3 ANTI-FLUORESCEIN SINGLE CHAIN ANTIBODY FRAGMENT (SCFV) |
1XH3 | B:1-99; A:182-272 | CONFORMATIONAL RESTRAINTS AND FLEXIBILITY OF 14-MERIC PEPTIDES IN COMPLEX WITH HLA-B*3501 |
1XIW | C:1-107; D:1-122; H:1-122; A:12-102; E:12-98; B:1-74; F:2-72; G:1-107 | CRYSTAL STRUCTURE OF HUMAN CD3-E/D DIMER IN COMPLEX WITH A UCHT1 SINGLE-CHAIN ANTIBODY FRAGMENT |
1XR8 | B:1-99; A:182-272 | CRYSTAL STRUCTURES OF HLA-B*1501 IN COMPLEX WITH PEPTIDES FROM HUMAN UBCH6 AND EPSTEIN-BARR VIRUS EBNA-3 |
1XR9 | B:1-99; A:182-272 | CRYSTAL STRUCTURES OF HLA-B*1501 IN COMPLEX WITH PEPTIDES FROM HUMAN UBCH6 AND EPSTEIN-BARR VIRUS EBNA-3 |
1XZ0 | B:1-98; A:183-277; C:183-277; D:1-98 | CRYSTAL STRUCTURE OF CD1A IN COMPLEX WITH A SYNTHETIC MYCOBACTIN LIPOPEPTIDE |
1Y6K | R:104-206; R:2-103 | CRYSTAL STRUCTURE OF HUMAN IL-10 COMPLEXED WITH THE SOLUBLE IL-10R1 CHAIN |
1YA5 | A:1-98; B:1-98; A:99-198; B:99-197 | CRYSTAL STRUCTURE OF THE TITIN DOMAINS Z1Z2 IN COMPLEX WITH TELETHONIN |
1YDP | B:1A-99; A:182-272 | 1.9A CRYSTAL STRUCTURE OF HLA-G |
1YMM | D:9-104; A:82-183; E:120-246; B:92-189; E:3-119 | TCR/HLA-DR2B/MBP-PEPTIDE COMPLEX |
1YY9 | C:109-211; D:122-219; D:1-118; C:1-108 | STRUCTURE OF THE EXTRACELLULAR DOMAIN OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN COMPLEX WITH THE FAB FRAGMENT OF CETUXIMAB/ERBITUX/IMC-C225 |
1Z6J | T:3-105; T:106-211 | CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR |
1ZA6 | A:114-217; B:116-218; D:116-218; F:116-218; H:116-218; B:239-344; D:239-344; F:239-344; H:239-344; A:1-113; C:1-113; E:1-113; G:1-113; C:114-217; E:114-217; G:114-217; B:1-115; D:1-115; F:1-115; H:1-115 | THE STRUCTURE OF AN ANTITUMOR CH2-DOMAIN-DELETED HUMANIZED ANTIBODY |
1ZAG | A:184-273; B:184-273; C:184-273; D:184-273 | HUMAN ZINC-ALPHA-2-GLYCOPROTEIN |
1ZGL | R:0-118; V:0-118; P:-1-118; T:-1-118; A:82-181; D:82-181; G:82-181; J:82-181; T:119-247; R:119-240; P:119-244; V:119-244; K:93-189; E:93-189; B:93-189; H:93-189; M:1-115; S:1-115; Q:0-115; U:0-115 | CRYSTAL STRUCTURE OF 3A6 TCR BOUND TO MBP/HLA-DR2A |
1ZHK | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING 13-MER EBV ANTIGEN LPEPLPQGQLTAY |
1ZHL | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*3508 PRESENTING 13-MER EBV ANTIGEN LPEPLPQGQLTAY |
1ZLS | L:108-210; H:114-227; H:1-113; L:2-107 | FAB 2G12 + MAN4 |
1ZLU | L:108-211; H:114-227; M:114-227; H:1-113; M:1-113; K:108-211; K:2-107; L:2-107 | FAB 2G12 + MAN5 |
1ZLV | K:108-212; M:114-227; H:114-227; H:1-113; M:1-113; L:108-212; K:2-107; L:2-107 | FAB 2G12 + MAN7 |
1ZLW | L:108-210; H:114-228; M:114-227; H:1-113; M:1-113; K:108-211; K:2-107; L:2-107 | FAB 2G12 + MAN8 |
1ZSD | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING AN 11-MER EBV ANTIGEN EPLPQGQLTAY |
1ZT4 | B:0-99; C:183-281; A:183-277; D:0-99 | THE CRYSTAL STRUCTURE OF HUMAN CD1D WITH AND WITHOUT ALPHA-GALACTOSYLCERAMIDE |
1ZXQ | A:86-192; A:1-85 | THE CRYSTAL STRUCTURE OF ICAM-2 |
2A2Q | T:6-105; T:106-210 | COMPLEX OF ACTIVE-SITE INHIBITED HUMAN COAGULATION FACTOR VIIA WITH HUMAN SOLUBLE TISSUE FACTOR IN THE PRESENCE OF CA2+, MG2+, NA+, AND ZN2+ |
2A38 | B:1-99; C:1-99; A:1-98; A:99-194; B:100-194; C:100-194 | CRYSTAL STRUCTURE OF THE N-TERMINUS OF TITIN |
2A83 | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE GLUCAGON RECEPTOR (GR) PEPTIDE (RESIDUES 412-420) |
2A9M | L:3-147; M:2-148; H:1-148; I:1-148 | STRUCTURAL ANALYSIS OF A TIGHT-BINDING FLUORESCEIN-SCFV; APO FORM |
2A9N | L:3-149; M:2-148; H:1-148; I:1-148 | A MUTATION DESIGNED TO ALTER CRYSTAL PACKING PERMITS STRUCTURAL ANALYSIS OF A TIGHT-BINDING FLUORESCEIN-SCFV COMPLEX |
2AAV | A:-4-1956 | SOLUTION NMR STRUCTURE OF FILAMIN A DOMAIN 17 |
2ADF | L:108-209; H:120-218; H:1-119; L:1-107 | CRYSTAL STRUCTURE AND PARATOPE DETERMINATION OF 82D6A3, AN ANTITHROMBOTIC ANTIBODY DIRECTED AGAINST THE VON WILLEBRAND FACTOR A3-DOMAIN |
2AEI | T:5-105; T:106-211 | CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR AND 2-[[6-[3-(AMINOIMINOMETHYL)PHENOXY]-3,5-DIFLURO-4-[(1-METHYL-3-PHENYLPROPYL)AMINO]-2-PYRIDINYL]OXY]-BENZOIC ACID |
2AER | T:5-105; T:106-206 | CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX. |
2AEW | B:132-233; A:132-233; A:29-131; B:31-131 | A MODEL FOR GROWTH HORMONE RECEPTOR ACTIVATION BASED ON SUBUNIT ROTATION WITHIN A RECEPTOR DIMER |
2AGJ | L:110-212; L:1-109; H:2-120; H:121-221 | CRYSTAL STRUCTURE OF A GLYCOSYLATED FAB FROM AN IGM CRYOGLOBULIN WITH PROPERTIES OF A NATURAL PROTEOLYTIC ANTIBODY |
2AJ3 | A:110-211; B:114-212; D:114-212; F:114-212; B:2-113; D:2-113; F:2-113; C:110-211; E:110-211; A:2-108; C:2-108; E:2-108 | CRYSTAL STRUCTURE OF A CROSS-REACTIVE HIV-1 NEUTRALIZING CD4-BINDING SITE ANTIBODY FAB M18 |
2AK4 | B:1-99; U:3-118; E:3-118; J:3-118; P:3-118; G:1-99; L:1-99; R:1-99; E:119-244; J:119-244; P:119-244; U:119-244; D:1-116; I:1-116; N:1-116; T:1-116; A:182-272; F:182-272; K:182-272; Q:182-272 | CRYSTAL STRUCTURE OF SB27 TCR IN COMPLEX WITH HLA-B*3508-13MER PEPTIDE |
2ARW | A:1-103 | THE SOLUTION STRUCTURE OF THE MEMBRANE PROXIMAL CYTOKINE RECEPTOR DOMAIN OF THE HUMAN INTERLEUKIN-6 RECEPTOR |
2AV1 | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF HTLV-1 TAX PEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2 WITH THE E63Q AND K66A MUTATIONS IN THE HEAVY CHAIN. |
2AV7 | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF HTLV-1 TAX PEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2 WITH THE K66A MUTATION IN THE HEAVY CHAIN. |
2AW2 | X:34-140; A:34-143 | CRYSTAL STRUCTURE OF THE HUMAN BTLA-HVEM COMPLEX |
2AXF | B:1-99; A:182-272 | THE IMMUNOGENICITY OF A VIRAL CYTOTOXIC T CELL EPITOPE IS CONTROLLED BY ITS MHC-BOUND CONFORMATION |
2AXG | B:1-99; A:182-272 | THE IMMUNOGENICITY OF A VIRAL CYTOTOXIC T CELL EPITOPE IS CONTROLLED BY ITS MHC-BOUND CONFORMATION |
2AXH | A:3-115; B:3-115; A:116-244; B:116-244 | CRYSTAL STRUCTURES OF T CELL RECEPTOR BETA CHAINS RELATED TO RHEUMATOID ARTHRITIS |
2AXJ | A:3-115; B:3-115; A:116-244; B:116-244 | CRYSTAL STRUCTURES OF T CELL RECEPTOR BETA CHAINS RELATED TO RHEUMATOID ARTHRITIS |
2B0S | H:114-225; L:2-107; H:1-113; L:108-211 | CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3 FAB 2219 IN COMPLEX WITH MN PEPTIDE |
2B1A | H:114-225; L:2-107; H:1-113; L:108-211 | CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3 FAB 2219 IN COMPLEX WITH UG1033 PEPTIDE |
2B1H | H:114-225; L:2-107; H:1-113; L:108-211 | CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3 FAB 2219 IN COMPLEX WITH UG29 PEPTIDE |
2B7D | T:6-205 | FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION, PRECLINICAL PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN A BABOON THROMBOSIS MODEL |
2B8O | T:6-105; T:106-210 | CRYSTAL STRUCTURE OF GLU-GLY-ARG-CHLOROMETHYL KETONE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX |
2BC4 | D:93-199; B:93-193; A:92-200; C:92-206 | CRYSTAL STRUCTURE OF HLA-DM |
2BCK | B:0-99; E:0-99; A:182-272; D:182-272 | CRYSTAL STRUCTURE OF HLA-A*2402 COMPLEXED WITH A TELOMERASE PEPTIDE |
2BK8 | A:0-96 | M1 DOMAIN FROM TITIN |
2BNQ | B:0-99; D:2-114; E:2-113; D:115-204; E:114-239; A:182-270 | STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES |
2BNR | B:0-99; A:182-270; D:2-114; E:2-113; D:115-204; E:114-239 | STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES |
2BNU | A:2-114; B:2-113; A:115-204; B:114-239 | STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES |
2BP3 | A:-1-1955; B:1865-1955 | CRYSTAL STRUCTURE OF FILAMIN A DOMAIN 17 AND GPIB ALPHA CYTOPLASMIC DOMAIN COMPLEX |
2BRQ | A:2236-2329; B:2236-2329 | CRYSTAL STRUCTURE OF THE FILAMIN A REPEAT 21 COMPLEXED WITH THE INTEGRIN BETA7 CYTOPLASMIC TAIL PEPTIDE |
2BSR | B:0-99; A:182-276 | CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705 |
2BSS | B:0-99; A:182-276 | CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705 |
2BST | B:0-99; A:182-276 | CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705 |
2BVO | B:1-99; A:182-272 | STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION |
2BVP | B:1-99; A:182-272 | STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION |
2BVQ | B:1-99; A:182-272 | STRUCTURES OF THREE HIV-1 HLA-B5703-PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG-TERM NON-PROGRESSION |
2C5D | C:131-218; D:131-218; C:27-130; D:27-130 | STRUCTURE OF A MINIMAL GAS6-AXL COMPLEX |
2C7U | B:0-99; A:182-270; D:182-270; E:0-99 | CONFLICTING SELECTIVE FORCES AFFECT CD8 T-CELL RECEPTOR CONTACT SITES IN AN HLA-A2 IMMUNODOMINANT HIV EPITOPE. |
2CD0 | A:1-108; B:1-108 | STRUCTURE OF HUMAN LAMBDA-6 LIGHT CHAIN DIMER WIL |
2CDE | A:2-114; C:2-114; E:2-114; B:2-116; D:2-116; F:2-116; B:117-242; D:117-242; F:117-242 | STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE SPECIFIC T CELL RECEPTORS - INKT-TCR |
2CDF | A:3-114; B:2-116; B:117-242 | STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE-SPECIFIC T CELL RECEPTORS (TCR 5E) |
2CDG | A:10-114; B:3-117; B:118-243 | STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE-SPECIFIC T CELL RECEPTORS (TCR 5B) |
2CIK | B:1-99; A:182-272 | INSIGHTS INTO CROSSREACTIVITY IN HUMAN ALLORECOGNITION: THE STRUCTURE OF HLA-B35011 PRESENTING AN EPITOPE DERIVED FROM CYTOCHROME P450. |
2CK2 | B:1-96; A:1-96 | STRUCTURE OF CORE-SWAPPED MUTANT OF FIBRONECTIN |
2CLR | B:0-99; E:0-99; A:182-275; D:182-275 | THREE DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING OUT ONE END OF A CLASS I MHC BINDING SITE |
2CMR | L:108-207; H:114-211; H:3-113; L:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 NEUTRALIZING ANTIBODY D5 FAB BOUND TO THE GP41 INNER-CORE MIMETIC 5-HELIX |
2CQV | A:1-114 | SOLUTION STRUCTURE OF THE EIGHTH IG-LIKE DOMAIN OF HUMAN MYOSIN LIGHT CHAIN KINASE |
2CUM | A:1-105 | THE SOLUTION STRUCTURE OF THE 33RD FIBRONECTIN TYPE III DOMAIN OF HUMAN TENASCIN-X |
2D31 | B:1-99; A:182-272; D:182-272; E:1-99 | CRYSTAL STRUCTURE OF DISULFIDE-LINKED HLA-G DIMER |
2D3V | A:96-195; A:3-95 | CRYSTAL STRUCTURE OF LEUKOCYTE IG-LIKE RECEPTOR A5 (LILRA5/LIR9/ILT11) |
2D4D | A:0-95 | THE CRYSTAL STRUCTURE OF HUMAN BETA2-MICROGLOBULIN, L39W W60F W95F MUTANT |
2D4F | A:0-97 | THE CRYSTAL STRUCTURE OF HUMAN BETA2-MICROGLOBULIN |
2D7T | L:1-110; H:1-116 | CRYSTAL STRUCTURE OF HUMAN ANTI POLYHYDROXYBUTYRATE ANTIBODY FV |
2D9Q | B:97-204; B:205-308 | CRYSTAL STRUCTURE OF THE HUMAN GCSF-RECEPTOR SIGNALING COMPLEX |
2DBJ | A:16-124 | SOLUTION STRUCTURES OF THE FN3 DOMAIN OF HUMAN PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER PRECURSOR |
2DD8 | H:114-216; L:2-108; H:2-113; L:109-213 | CRYSTAL STRUCTURE OF SARS-COV SPIKE RECEPTOR-BINDING DOMAIN COMPLEXED WITH NEUTRALIZING ANTIBODY |
2DF3 | A:24-144 | THE STRUCTURE OF SIGLEC-7 IN COMPLEX WITH ALPHA(2,3)/ALPHA(2,6) DISIALYL LACTOTETRAOSYL 2-(TRIMETHYLSILYL)ETHYL |
2DIC | A:7-100 | SOLUTION STRUCTURE OF THE 12TH FILAMIN DOMAIN FROM HUMAN FILAMIN-B |
2DJ4 | A:7-103 | SOLUTION STRUCTURE OF THE 13TH FILAMIN DOMAIN FROM HUMAN FILAMIN-B |
2DJS | A:13-100 | SOLUTION STRUCTURES OF THE FN3 DOMAIN OF HUMAN EPHRIN TYPE-B RECEPTOR 1 |
2DKS | A:1-130 | SOLUTION STRUCTURE OF THE FIRST IG-LIKE DOMAIN OF HUMAN CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 8 |
2DL2 | A:103-200; A:5-102 | KILLER IMMUNOGLOBULIN RECEPTOR 2DL2 |
2DLI | A:103-200; A:5-102 | KILLER IMMUNOGLOBULIN RECEPTOR 2DL2,TRIGONAL FORM |
2DM2 | A:1-110 | SOLUTION STRUCTURE OF THE FIRST IG DOMAIN OF HUMAN PALLADIN |
2DTQ | | [entry was replaced by entry 3AVE without any CATH domain information] |
2DTS | A:338-443; B:338-443; A:238-337; B:238-337 | CRYSTAL STRUCTURE OF THE DEFUCOSYLATED FC FRAGMENT FROM HUMAN IMMUNOGLOBULIN G1 |
2DYP | B:0-99; A:182-272; D:96-195; D:3-95 | CRYSTAL STRUCTURE OF LILRB2(LIR2/ILT4/CD85D) COMPLEXED WITH HLA-G |
2E7H | A:13-101 | SOLUTION STRUCTURE OF THE SECOND FN3 DOMAIN FROM HUMAN EPHRIN TYPE-B RECEPTOR 4 |
2E9W | A:208-310; B:208-310; A:311-412; B:311-412; A:117-207; B:117-207; B:413-507; A:413-507; A:33-116; B:33-116 | CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF KIT IN COMPLEX WITH STEM CELL FACTOR (SCF) |
2EC8 | A:208-311; A:312-411; A:11-116; A:117-207; A:412-508 | CRYSTAL STRUCTURE OF THE EXCTRACELLULAR DOMAIN OF THE RECEPTOR TYROSINE KINASE, KIT |
2EC9 | U:91-210; T:6-80 | CRYSTAL STRUCTURE ANALYSIS OF HUMAN FACTOR VIIA , SOULUBLE TISSUE FACTOR COMPLEXED WITH BCX-3607 |
2EED | A:1-101 | SOLUTION STRUCTURE OF THE 24TH FILAMIN DOMAIN FROM HUMAN FILAMIN-B |
2EIZ | A:1-107; B:1-113 | CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV MUTANT(HW47Y)-HEN LYSOZYME COMPLEX |
2EKS | A:1-107; B:1-113 | CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV-HEN LYSOZYME COMPLEX |
2ESV | B:0-99; A:182-272; D:4-115; E:3-118; E:119-247 | STRUCTURE OF THE HLA-E-VMAPRTLIL/KK50.4 TCR COMPLEX |
2EYR | A:1-116; B:3-118; B:119-244 | A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION |
2EYS | A:1-116; B:3-118; B:119-244 | A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION |
2EYT | A:1-116; C:1-116; B:3-118; D:3-118; B:119-244; D:119-244 | A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION |
2F53 | B:0-99; A:182-270; D:-1-113; E:-1-112; E:113-238 | DIRECTED EVOLUTION OF HUMAN T-CELL RECEPTOR CDR2 RESIDUES BY PHAGE DISPLAY DRAMATICALLY ENHANCES AFFINITY FOR COGNATE PEPTIDE-MHC WITHOUT APPARENT CROSS-REACTIVITY |
2F54 | B:0-99; A:182-270; F:182-270; D:1-113; K:0-113; E:1-112; L:1-112; E:113-238; L:113-238; G:0-99 | DIRECTED EVOLUTION OF HUMAN T CELL RECEPTOR CDR2 RESIDUES BY PHAGE DISPLAY DRAMATICALLY ENHANCES AFFINITY FOR COGNATE PEPTIDE-MHC WITHOUT INCREASING APPARENT CROSS-REACTIVITY |
2F5A | L:108-211; H:133-231; H:1-132; L:1-107 | CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5 |
2F5B | L:108-211; H:133-232; H:1-132; L:1-107 | CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH ITS GP41 EPITOPE |
2F8O | A:4-97; B:4-97 | A NATIVE TO AMYLOIDOGENIC TRANSITION REGULATED BY A BACKBONE TRIGGER |
2F8V | B:1-98; A:2-98; D:2-98; C:4-98; B:99-197; A:99-195; C:99-194; D:99-194 | STRUCTURE OF FULL LENGTH TELETHONIN IN COMPLEX WITH THE N-TERMINUS OF TITIN |
2F9B | T:6-205 | DISCOVERY OF NOVEL HETEROCYCLIC FACTOR VIIA INHIBITORS |
2FB4 | H:119-218; L:1-109; L:110-210; H:1-118 | DIR PRIMAERSTRUKTUR DES KRISTALLISIERBAREN MONOKLONALEN IMMUNOGLOBULINS IGG1 KOL. II. AMINOSAEURESEQUENZ DER L-KETTE, LAMBDA-TYP, SUBGRUPPE I (GERMAN) |
2FCB | A:92-178; A:6-91 | HUMAN FC GAMMA RECEPTOR IIB ECTODOMAIN (CD32) |
2FD6 | L:108-210; H:115-208; H:1-114; L:1-107 | STRUCTURE OF HUMAN UROKINASE PLASMINOGEN ACTIVATOR IN COMPLEX WITH UROKINASE RECEPTOR AND AN ANTI-UPAR ANTIBODY AT 1.9 A |
2FDB | P:2151-2250; R:3151-3250; P:2251-2357; R:3251-3357 | CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR (FGF)8B IN COMPLEX WITH FGF RECEPTOR (FGFR) 2C |
2FIR | T:6-105; T:106-210 | CRYSTAL STRUCTURE OF DFPR-VIIA/STF |
2FJF | A:109-211; B:121-223; D:121-223; F:121-223; H:121-223; I:121-223; K:121-223; N:121-223; P:121-223; R:121-223; T:121-223; V:121-223; X:121-223; B:1-120; D:1-120; F:1-120; H:1-120; I:1-120; K:1-120; N:1-120; P:1-120; R:1-120; T:1-120; V:1-120; X:1-120; C:109-211; E:109-211; G:109-211; J:109-211; L:109-211; M:109-211; O:109-211; Q:109-211; S:109-211; U:109-211; W:109-211; A:1-108; C:1-108; E:1-108; G:1-108; J:1-108; L:1-108; M:1-108; O:1-108; Q:1-108; S:1-108; U:1-108; W:1-108 | STRUCTURE OF THE G6 FAB, A PHAGE DERIVED VEGF BINDING FAB |
2FJG | A:109-211; B:121-223; H:121-223; B:1-120; H:1-120; L:109-211; A:1-108; L:1-108 | STRUCTURE OF THE G6 FAB, A PHAGE DERIVED FAB FRAGMENT, IN COMPLEX WITH VEGF |
2FJH | L:109-214; B:122-224; H:122-224; B:1-121; H:1-121; A:109-211; A:1-108; L:1-108 | STRUCTURE OF THE B20-4 FAB, A PHAGE DERIVED FAB FRAGMENT, IN COMPLEX WITH VEGF |
2FL5 | B:114-225; D:114-225; F:114-225; H:114-225; A:1-107; C:1-107; E:1-107; L:1-107; A:108-212; C:108-212; E:108-212; L:108-212; B:1-113; D:1-113; F:1-113; H:1-113 | COFACTOR-CONTAINING ANTIBODIES: CRYSTAL STRUCTURE OF THE ORIGINAL YELLOW ANTIBODY |
2FLB | T:6-205 | DISCOVERY OF A NOVEL HYDROXY PYRAZOLE BASED FACTOR IXA INHIBITOR |
2FLR | T:6-205 | NOVEL 5-AZAINDOLE FACTOR VIIA INHIBITORS |
2FNB | A:1-95 | NMR STRUCTURE OF THE FIBRONECTIN ED-B DOMAIN, NMR, 20 STRUCTURES |
2FSE | A:82-181; C:82-180; B:93-190; D:93-189 | CRYSTALLOGRAPHIC STRUCTURE OF A RHEUMATOID ARTHRITIS MHC SUSCEPTIBILITY ALLELE, HLA-DR1 (DRB1*0101), COMPLEXED WITH THE IMMUNODOMINANT DETERMINANT OF HUMAN TYPE II COLLAGEN |
2FX7 | L:109-211; L:1-108; H:110-228; H:1-109 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A 16-RESIDUE PEPTIDE ENCOMPASSING THE 4E10 EPITOPE ON GP41 |
2FX8 | L:109-211; L:1-108; M:1-108; N:1-108; O:1-108; H:110-227; I:110-227; J:110-227; K:110-227; H:1-109; I:1-109; J:1-109; K:1-109; M:109-211; N:109-211; O:109-211 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH AN AIB-INDUCED PEPTIDE ENCOMPASSING THE 4E10 EPITOPE ON GP41 |
2FX9 | L:109-211; L:1-108; M:1-108; H:110-227; I:110-227; H:1-109; I:1-109; M:109-211 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A THIOETHER-LINKED PEPTIDE ENCOMPASSING THE 4E10 EPITOPE ON GP41 |
2FYY | B:1-99; A:182-272 | THE ROLE OF T CELL RECEPTOR ALPHA GENES IN DIRECTING HUMAN MHC RESTRICTION |
2FZ3 | B:1-99; A:182-272 | THE ROLE OF T CELL RECEPTOR ALPHA GENES IN DIRECTING HUMAN MHC RESTRICTION |
2G5R | A:24-144 | CRYSTAL STRUCTURE OF SIGLEC-7 IN COMPLEX WITH METHYL-9-(AMINOOXALYL-AMINO)-9-DEOXYNEU5AC (OXAMIDO-NEU5AC) |
2G75 | A:114-214; C:114-214; B:2-108; D:2-108; A:2-113; C:2-113; B:109-211; D:109-211 | CRYSTAL STRUCTURE OF ANTI-SARS M396 ANTIBODY |
2G9H | A:82-181; B:93-190 | CRYSTAL STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN I (SEI) IN COMPLEX WITH A HUMAN MHC CLASS II MOLECULE |
2GI7 | A:89-183; B:89-183; B:0-88; A:2-88 | CRYSTAL STRUCTURE OF HUMAN PLATELET GLYCOPROTEIN VI (GPVI) |
2GIT | B:0-99; E:0-99; A:182-270; D:182-270 | HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE MODIFIED HTLV-1 TAX (Y5K-4-[3-INDOLYL]-BUTYRIC ACID) PEPTIDE |
2GJ6 | B:0-99; A:182-270; E:3-117; D:117-206; E:118-243; D:1-116 | THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE MODIFIED HTLV-1 TAX (Y5K-4-[3-INDOLYL]-BUTYRIC ACID) PEPTIDE |
2GK2 | A:1-107; B:1-107 | CRYSTAL STRUCTURE OF THE N TERMINAL DOMAIN OF HUMAN CEACAM1 |
2GT9 | B:0-99; E:0-99; A:182-270; D:182-270 | HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE DECAMERIC MELAN-A/MART-1(26-35) PEPTIDE |
2GTW | B:0-99; E:0-99; A:182-270; D:182-270 | HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE NONAMERIC MELAN-A/MART-1(27-35) PEPTIDE HAVING A27L SUBSTITUTION |
2GTZ | B:0-99; E:0-99; A:182-270; D:182-270 | HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE NONAMERIC MELAN-A/MART-1(27-35) PEPTIDE HAVING A28L SUBSTITUTION |
2GUO | B:0-99; A:182-270; D:182-270; E:0-99 | HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE NATIVE NONAMERIC MELAN-A/MART-1(27-35) PEPTIDE |
2GW5 | A:97-198; A:3-96 | CRYSTAL STRUCTURE OF LIR-2 (ILT4) AT 1.8 : DIFFERENCES FROM LIR-1 (ILT2) IN REGIONS IMPLICATED IN THE BINDING OF THE CYTOMEGALOVIRUS CLASS I MHC HOMOLOG UL18 |
2GY5 | A:23-121; A:347-445; A:122-211 | TIE2 LIGAND-BINDING DOMAIN CRYSTAL STRUCTURE |
2GY7 | B:23-121; B:347-445; B:122-211 | ANGIOPOIETIN-2/TIE2 COMPLEX CRYSTAL STRUCTURE |
2GYS | A:109-215; B:109-215; B:320-418; A:320-418; A:1-95; B:1-95; A:218-308; B:218-308 | 2.7 A STRUCTURE OF THE EXTRACELLULAR DOMAINS OF THE HUMAN BETA COMMON RECEPTOR INVOLVED IN IL-3, IL-5, AND GM-CSF SIGNALLING |
2H26 | B:1-99; A:183-278 | HUMAN CD1B IN COMPLEX WITH ENDOGENOUS PHOSPHATIDYLCHOLINE AND SPACER |
2H32 | H:1-119; H:120-221; A:1-111 | CRYSTAL STRUCTURE OF THE PRE-B CELL RECEPTOR |
2H3N | A:2-100; C:1-99 | CRYSTAL STRUCTURE OF A SURROGATE LIGHT CHAIN (LAMBDA5 AND VPREB) HOMODIMER |
2H6P | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING THE HUMAN CYTOCHROME P450 DERIVED PEPTIDE, KPIVVLHGY |
2H9G | A:109-211; B:114-213; H:114-213; B:1-113; H:1-113; L:109-211; A:1-108; L:1-108 | CRYSTAL STRUCTURE OF PHAGE DERIVED FAB BDF1 WITH HUMAN DEATH RECEPTOR 5 (DR5) |
2HFF | A:108-213; B:114-214; H:114-213; H:1-113; B:1-113; L:108-210; A:2-107; L:1-107 | CRYSTAL STRUCTURE OF CB2 FAB |
2HFG | L:108-212; H:114-214; H:1-113; L:1-107 | CRYSTAL STRUCTURE OF HBR3 BOUND TO CB3S-FAB |
2HFT | A:1-107; A:108-211 | THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR AT 1.7 ANGSTROMS RESOLUTION |
2HJK | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B5703 AND HIV-1 PEPTIDE |
2HJL | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B5703 AND HIV-1 PEPTIDE |
2HLA | B:1-99; A:182-270 | SPECIFICITY POCKETS FOR THE SIDE CHAINS OF PEPTIDE ANTIGENS IN HLA-AW68 |
2HN7 | B:1-99; A:182-274 | HLA-A*1101 IN COMPLEX WITH HBV PEPTIDE HOMOLOGUE |
2HP4 | A:1-114; B:1-114 | COMPUTATIONAL DESIGN AND CRYSTAL STRUCTURE OF AN ENHANCED AFFINITY MUTANT HUMAN CD8-ALPHA-ALPHA CO-RECEPTOR |
2HRL | A:25-144 | SIGLEC-7 IN COMPLEX WITH GT1B |
2HYM | A:1-106; A:107-212 | NMR BASED DOCKING MODEL OF THE COMPLEX BETWEEN THE HUMAN TYPE I INTERFERON RECEPTOR AND HUMAN INTERFERON ALPHA-2 |
2IAL | B:2-111; D:2-111; A:1-108; C:1-108; B:112-237; D:112-237 | STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR |
2IAM | D:2-111; A:82-181; C:1-108; D:112-237; B:93-190 | STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR |
2IAN | E:3-111; O:3-111; T:3-111; J:2-111; A:82-181; F:82-181; K:82-181; P:82-181; D:1-108; I:1-108; N:1-108; S:1-108; E:112-237; J:112-237; O:112-237; T:112-237; L:93-190; Q:93-190; B:93-190; G:93-190 | STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR |
2ICW | L:3-113; J:1-113; A:82-181; D:82-181; E:93-190; B:93-190; K:2-110; I:1-110 | CRYSTAL STRUCTURE OF A COMPLETE TERNARY COMPLEX BETWEEN TCR, SUPERANTIGEN, AND PEPTIDE-MHC CLASS II MOLECULE |
2IFG | A:283-381; B:283-381; A:193-282; B:193-282 | STRUCTURE OF THE EXTRACELLULAR SEGMENT OF HUMAN TRKA IN COMPLEX WITH NERVE GROWTH FACTOR |
2IG2 | H:119-221; L:1-109; L:110-210; H:1-118 | DIR PRIMAERSTRUKTUR DES KRISTALLISIERBAREN MONOKLONALEN IMMUNOGLOBULINS IGG1 KOL. II. AMINOSAEURESEQUENZ DER L-KETTE, LAMBDA-TYP, SUBGRUPPE I (GERMAN) |
2ILL | A:98-195; A:1-97 | ANOMALOUS SUBSTRUCTURE OF TITIN-A168169 |
2IPK | A:82-181; B:93-190 | CRYSTAL STRUCTURE OF THE MHC CLASS II MOLECULE HLA-DR1 IN COMPLEX WITH THE FLUOROGENIC PEPTIDE, ACPKXVKQNTLKLAT (X=3-[5-(DIMETHYLAMINO)-1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL]-L-ALANINE) AND THE SUPERANTIGEN, SEC3 VARIANT 3B2 |
2IWG | A:338-443; D:338-443; A:238-337; D:238-337 | COMPLEX BETWEEN THE PRYSPRY DOMAIN OF TRIM21 AND IGG FC |
2J6E | A:338-443; B:338-443; L:1-108; M:1-108; H:1-113; I:1-113; L:109-208; M:109-208; A:238-337; B:238-337; I:114-214; H:114-214 | CRYSTAL STRUCTURE OF AN AUTOIMMUNE COMPLEX BETWEEN A HUMAN IGM RHEUMATOID FACTOR AND IGG1 FC REVEALS A NOVEL FC EPITOPE AND EVIDENCE FOR AFFINITY MATURATION |
2J8H | A:98-195; A:1-97 | STRUCTURE OF THE IMMUNOGLOBULIN TANDEM REPEAT A168-A169 OF TITIN |
2J8O | A:98-195; B:98-195; A:0-97; B:1-97 | STRUCTURE OF THE IMMUNOGLOBULIN TANDEM REPEAT OF TITIN A168-A169 |
2JB5 | H:121-222; L:3-112; H:3-120; L:113-214 | FAB FRAGMENT IN COMPLEX WITH SMALL MOLECULE HAPTEN, CRYSTAL FORM-1 |
2JB6 | B:121-221; H:121-221; L:4-112; A:3-112; H:3-120; B:3-120; A:113-214; L:113-214 | FAB FRAGMENT IN COMPLEX WITH SMALL MOLECULE HAPTEN, CRYSTAL FORM-2 |
2JCC | B:0-99; A:182-270; H:182-270; F:3-117; M:3-117; I:0-99; F:118-245; M:118-245; E:1-116; L:1-116 | AH3 RECOGNITION OF MUTANT HLA-A2 W167A |
2JLL | A:593-689 | CRYSTAL STRUCTURE OF NCAM2 IGIV-FN3II |
2K7P | A:1866-1956 | FILAMIN A IG-LIKE DOMAINS 16-17 |
2K7Q | A:-3-1968,A:2047-2141 | FILAMIN A IG-LIKE DOMAINS 18-19 |
2KBG | A:1-102 | SOLUTION STRUCTURE OF THE SECOND FIBRONECTIN TYPE-III MODULE OF NCAM2 |
2KH2 | B:130-248 | SOLUTION STRUCTURE OF A SCFV-IL-1B COMPLEX |
2KZ1 | B:11-106; B:107-206 | INTER-MOLECULAR INTERACTIONS IN A 44 KDA INTERFERON-RECEPTOR COMPLEX DETECTED BY ASYMMETRIC BACK-PROTONATION AND 2D NOESY |
2LVE | A:1-107 | RECOMBINANT LEN |
2MCG | 1:2-111; 2:2-111; 1:112-216; 2:112-212 | THREE-DIMENSIONAL STRUCTURE OF A LIGHT CHAIN DIMER CRYSTALLIZED IN WATER. CONFORMATIONAL FLEXIBILITY OF A MOLECULE IN TWO CRYSTAL FORMS |
2NMS | A:18-129 | THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF THE INHIBITOR RECEPTOR EXPRESSED ON MYELOID CELLS IREM-1 |
2NNA | A:82-180; B:93-190 | STRUCTURE OF THE MHC CLASS II MOLECULE HLA-DQ8 BOUND WITH A DEAMIDATED GLUTEN PEPTIDE |
2NQC | A:2482-2578 | CRYSTAL STRUCTURE OF IG-LIKE DOMAIN 23 FROM HUMAN FILAMIN C |
2NTS | P:3-118; P:119-245 | CRYSTAL STRUCTURE OF SEK-HVB5.1 |
2NW2 | A:1-116; B:1-118; B:119-244 | CRYSTAL STRUCTURE OF ELS4 TCR AT 1.4A |
2NW3 | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*3508 PRESENTING EBV PEPTIDE EPLPQGQLTAY AT 1.7A |
2NX5 | B:1-99; D:1-116; I:1-116; N:1-116; T:1-116; E:1-118; J:1-118; P:1-118; U:1-118; E:119-244; J:119-244; P:119-244; G:1-99; U:119-244; L:1-99; R:1-99; A:182-272; F:182-272; K:182-272; Q:182-272 | CRYSTAL STRUCTURE OF ELS4 TCR BOUND TO HLA-B*3501 PRESENTING EBV PEPTIDE EPLPQGQLTAY AT 1.7A |
2NZI | A:95-194; B:95-194; A:-1-93; B:-1-93; A:196-289; B:196-289 | CRYSTAL STRUCTURE OF DOMAINS A168-A170 FROM TITIN |
2OCF | D:2-94 | HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND THE E2#23 FN3 MONOBODY |
2OJE | A:82-181; E:82-181; B:93-190; F:93-190 | MYCOPLASMA ARTHRITIDIS-DERIVED MITOGEN COMPLEXED WITH CLASS II MHC MOLECULE HLA-DR1/HA COMPLEX IN THE PRESENCE OF EDTA |
2OLD | A:2-112; B:2-112; A:113-213; B:113-213 | BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P3(2)21 CRYSTAL FORM |
2OM5 | A:101-205; A:4-100; A:295-384; A:206-294 | N-TERMINAL FRAGMENT OF HUMAN TAX1 |
2OMB | A:2-112; B:2-112; C:2-112; D:2-112; D:113-214; A:113-213; B:113-213; C:113-213 | BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P3(1)21 CRYSTAL FORM |
2OMN | A:2-112; B:2-112; A:113-213; B:113-213 | BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P4(3)2(1)2 CRYSTAL FORM |
2OQJ | A:108-212; B:114-228; E:114-228; H:114-228; K:114-228; B:1-113; E:1-113; H:1-113; K:1-113; D:108-212; G:108-212; J:108-212; A:2-107; D:2-107; G:2-107; J:2-107 | CRYSTAL STRUCTURE ANALYSIS OF FAB 2G12 IN COMPLEX WITH PEPTIDE 2G12.1 |
2OZ4 | L:109-211; H:115-214; H:1-114; L:1-108 | STRUCTURAL PLASTICITY IN IGSF DOMAIN 4 OF ICAM-1 MEDIATES CELL SURFACE DIMERIZATION |
2P5E | B:0-99; D:0-114; E:1-112; E:113-238; A:182-270 | CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEAL NATIVE DIAGONAL BINDING GEOMETRY |
2P5W | B:0-99; A:182-270; D:1-114; E:0-112; E:113-238 | CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEAL NATIVE DIAGONAL BINDING GEOMETRY |
2P8L | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELLELDKWASLWN |
2P8M | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELLELDKWASLWN IN NEW CRYSTAL FORM |
2P8P | A:108-211; B:114-214; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE LELDKWASLW[N-AC] |
2PO6 | B:1-99; C:1-116; G:1-116; D:2-118; H:2-118; D:119-244; H:119-244; A:183-280; E:183-277; F:2-99 | CRYSTAL STRUCTURE OF CD1D-LIPID-ANTIGEN COMPLEXED WITH BETA-2-MICROGLOBULIN, NKT15 ALPHA-CHAIN AND NKT15 BETA-CHAIN |
2PR4 | L:108-211; H:133-232; H:1-132; L:1-107 | CRYSTAL STRUCTURE OF FAB' FROM THE HIV-1 NEUTRALIZING ANTIBODY 2F5 |
2PUQ | T:6-105; T:106-209 | CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA IN COMPLEX WITH SOLUBLE TISSUE FACTOR |
2PW1 | A:108-211; B:114-214; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWNSL |
2PW2 | A:108-211; B:114-214; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELDKWKSL |
2PYE | B:0-99; A:182-270; D:0-114; E:0-112; E:113-238 | CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEALNATIVE DIAGONAL BINDING GEOMETRY TCR CLONE C5C1 COMPLEXED WITH MHC |
2PYF | A:1-114; B:1-112; B:113-238 | CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEALNATIVE DIAGONAL BINDING GEOMETRY UNBOUND TCR CLONE 5-1 |
2Q1E | A:-1-107; B:-1-107; C:-1-107; D:-1-107 | ALTERED DIMER INTERFACE DECREASES STABILITY IN AN AMYLOIDOGENIC KAPPA1 BENCE JONES PROTEIN. |
2Q20 | A:0-107; B:-1-107 | STRUCTURE OF THE GERMLINE VK1 O18/O8 LIGHT CHAIN VARIABLE DOMAIN HOMODIMER |
2Q6W | A:82-182; D:82-182; B:94-190; E:94-190 | THE STRUCTURE OF HLA-DRA, DRB3*0101 (DR52A) WITH BOUND PLATELET INTEGRIN PEPTIDE ASSOCIATED WITH FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA |
2Q87 | C:5-110; A:2-108; B:5-111 | THE CRYSTAL STRUCTURE OF THE HUMAN IRP60 ECTODOMAIN |
2QEJ | A:342-450; B:342-450; A:240-341; B:242-341 | CRYSTAL STRUCTURE OF A STAPHYLOCOCCUS AUREUS PROTEIN (SSL7) IN COMPLEX WITH FC OF HUMAN IGA1 |
2QL1 | A:338-443; A:238-337 | STRUCTURAL CHARACTERIZATION OF A MUTATED, ADCC-ENHANCED HUMAN FC FRAGMENT |
2QQK | L:109-211; H:114-220; H:1-113; L:1-108 | NEUROPILIN-2 A1A2B1B2 DOMAINS IN COMPLEX WITH A SEMAPHORIN-BLOCKING FAB |
2QQL | L:109-214; H:114-216; H:1-113; L:1-108 | NEUROPILIN-2 A1A2B1B2 DOMAINS IN COMPLEX WITH A SEMAPHORIN-BLOCKING FAB |
2QQN | L:108-211; H:114-220; H:1-113; L:1-107 | NEUROPILIN-1 B1 DOMAIN IN COMPLEX WITH A VEGF-BLOCKING FAB |
2QR0 | A:109-211; B:114-213; F:114-213; H:114-213; L:114-213; N:114-213; R:114-213; T:114-213; X:114-213; B:1-113; F:1-113; H:1-113; L:1-113; N:1-113; R:1-113; T:1-113; X:1-113; E:109-211; G:109-211; K:109-211; M:109-211; Q:109-211; S:109-211; W:109-211; A:1-108; E:1-108; G:1-108; K:1-108; M:1-108; Q:1-108; S:1-108; W:1-108 | STRUCTURE OF VEGF COMPLEXED TO A FAB CONTAINING TYR AND SER IN THE CDRS |
2QSC | L:108-211; H:114-226; H:1-113; L:1-107 | CRYSTAL STRUCTURE ANALYSIS OF ANTI-HIV-1 V3-FAB F425-B4E8 IN COMPLEX WITH A V3-PEPTIDE |
2QSQ | B:1-108; A:1-110 | CRYSTAL STRUCTURE OF THE N-TERMINAL DOMAIN OF CARCINOEMBRYONIC ANTIGEN (CEA) |
2QST | A:1-110; B:1-110 | CRYSTAL STRUCTURE OF THE V39C MUTANT OF THE N-TERMINAL DOMAIN OF CARCINOEMBRYONIC ANTIGEN (CEA) |
2R0K | L:109-214; H:114-216; H:1-113; L:1-108 | PROTEASE DOMAIN OF HGFA WITH INHIBITOR FAB58 |
2R4R | L:109-211; H:115-217; H:1-114; L:1-108 | CRYSTAL STRUCTURE OF THE HUMAN BETA2 ADRENOCEPTOR |
2R4S | L:109-211; H:115-217; H:1-114; L:1-108 | CRYSTAL STRUCTURE OF THE HUMAN BETA2 ADRENOCEPTOR |
2RB8 | A:801-893 | HIGH RESOLUTION DESIGN OF A PROTEIN LOOP |
2RFX | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*5701, PRESENTING THE SELF PEPTIDE, LSSPVTKSF |
2RHE | A:1-114 | STRUCTURE OF A NOVEL BENCE-JONES PROTEIN (RHE) FRAGMENT AT 1.6 ANGSTROMS RESOLUTION |
2RQ8 | A:0-97 | SOLUTION NMR STRUCTURE OF TITIN I27 DOMAIN MUTANT |
2SEB | A:82-180; B:92-190 | X-RAY CRYSTAL STRUCTURE OF HLA-DR4 COMPLEXED WITH A PEPTIDE FROM HUMAN COLLAGEN II |
2UWE | B:0-99; A:182-270; H:182-270; F:3-117; M:3-117; I:0-99; F:118-245; M:118-245; E:1-116; L:1-116 | LARGE CDR3A LOOP ALTERATION AS A FUNCTION OF MHC MUTATION |
2UZI | L:4-107; H:1-114 | CRYSTAL STRUCTURE OF HRAS(G12V) - ANTI-RAS FV COMPLEX |
2V17 | L:109-211; H:124-222; H:1-123; L:1-108 | STRUCTURE OF THE COMPLEX OF ANTIBODY MN423 WITH A FRAGMENT OF TAU PROTEIN |
2V2W | B:0-99; E:0-99; A:182-270; D:182-270 | T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT |
2V2X | B:0-99; E:0-99; A:182-270; D:182-270 | T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT. |
2V44 | | [entry was replaced by entry 2XY2 without any CATH domain information] |
2VAJ | A:1-93 | CRYSTAL STRUCTURE OF NCAM2 IG1 (I4122 CELL UNIT) |
2VB5 | A:0-99 | SOLUTION STRUCTURE OF W60G MUTANT OF HUMAN BETA2-MICROGLOBULIN |
2VC2 | L:108-211; H:120-216; H:1-119; L:1-107 | RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST L-739758 |
2VDK | L:108-211; H:120-216; H:1-119; L:1-107 | RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE |
2VDL | L:108-211; H:120-216; H:1-119; L:1-107 | RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE |
2VDM | L:108-211; H:120-216; H:1-119; L:1-107 | RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST TIROFIBAN |
2VDN | L:108-211; H:120-216; H:1-119; L:1-107 | RE-REFINEMENT OF INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO ANTAGONIST EPTIFIBATIDE |
2VDO | L:108-211; H:120-216; H:1-119; L:1-107 | INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO FIBRINOGEN GAMMA CHAIN PEPTIDE, HHLGGAKQAGDV |
2VDP | L:108-211; H:120-216; H:1-119; L:1-107 | INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO FIBRINOGEN GAMMA CHAIN PEPTIDE,LGGAKQAGDV |
2VDQ | L:108-211; H:120-216; H:1-119; L:1-107 | INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO A CHIMERIC FIBRINOGEN GAMMA CHAIN PEPTIDE, HHLGGAKQRGDV |
2VDR | L:108-211; H:120-216; H:1-119; L:1-107 | INTEGRIN ALPHAIIBBETA3 HEADPIECE BOUND TO A CHIMERIC FIBRINOGEN GAMMA CHAIN PEPTIDE, LGGAKQRGDV |
2VH5 | L:4-107; H:1-114 | CRYSTAL STRUCTURE OF HRAS(G12V) - ANTI-RAS FV (DISULFIDE FREE MUTANT) COMPLEX |
2VLJ | B:0-99; A:182-270; D:3-111; E:5-115; E:116-244 | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN |
2VLK | B:0-99; A:182-270; D:3-111; E:5-115; E:116-244 | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN |
2VLL | B:0-99; E:0-99; A:182-270; D:182-270 | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN |
2VLM | D:3-111; E:5-115; E:116-244 | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN |
2VLR | B:0-99; A:182-270; F:182-270; D:3-111; I:3-111; E:5-115; J:5-115; G:0-99; E:116-244; J:116-244 | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN |
2VWE | C:107-210; E:114-212; L:114-212; J:107-210; E:1-113; L:1-113; C:1-106A; J:1-106A | CRYSTAL STRUCTURE OF VASCULAR ENDOTHELIAL GROWTH FACTOR-B IN COMPLEX WITH A NEUTRALIZING ANTIBODY FAB FRAGMENT |
2VXS | I:114-216; K:114-215; H:114-216; J:114-213; O:109-209; H:1-113; I:1-113; J:1-113; K:1-113 | STRUCTURE OF IL-17A IN COMPLEX WITH A POTENT, FULLY HUMAN NEUTRALISING ANTIBODY |
2VXV | L:109-211; H:114-214; H:1-113 | CRYSTAL STRUCTURE OF HUMAN IGG ABT-325 FAB FRAGMENT |
2VYR | G:1-123; E:1-124; F:1-124; I:1-124; J:1-124; K:1-124; L:1-124; H:1-125 | STRUCTURE OF HUMAN MDM4 N-TERMINAL DOMAIN BOUND TO A SINGLE DOMAIN ANTIBODY |
2W9E | L:108-210; H:117-215; H:1-116 | STRUCTURE OF ICSM 18 (ANTI-PRP THERAPEUTIC ANTIBODY) FAB FRAGMENT COMPLEXED WITH HUMAN PRP FRAGMENT 119-231 |
2WAH | A:338-444; B:338-445; B:237-337; A:238-337 | CRYSTAL STRUCTURE OF AN IGG1 FC GLYCOFORM (MAN9GLCNAC2) |
2WBJ | C:8-112; G:10-112; A:82-180; E:82-180; H:142-268; D:142-269; F:92-190; B:92-188; H:1-141; D:-1-141 | TCR COMPLEX |
2WIM | A:19-112; B:19-112; A:113-208; B:113-208; A:209-298; B:209-294 | CRYSTAL STRUCTURE OF NCAM2 IG1-3 |
2WUB | L:109-214; H:114-217; R:114-209; H:1-113; R:1-113; Q:109-214 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP |
2WUC | L:109-214; H:114-217; H:1-113 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP AND AC-KQLR-CHLOROMETHYLKETONE |
2X4N | B:0-99; A:182-270; D:181-269; E:0-99 | CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO RESIDUAL FRAGMENTS OF A PHOTOCLEAVABLE PEPTIDE THAT IS CLEAVED UPON UV-LIGHT TREATMENT |
2X4O | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO HIV-1 ENVELOPE PEPTIDE ENV120-128 |
2X4P | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PHOTOCLEAVABLE PEPTIDE |
2X4Q | B:1-98; A:182-270; D:182-270; E:1-98 | CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PHOTOCLEAVABLE PEPTIDE |
2X4R | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO CYTOMEGALOVIRUS (CMV) PP65 EPITOPE |
2X4S | B:1-98; A:182-270; D:182-270; E:1-98 | CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PEPTIDE REPRESENTING THE EPITOPE OF THE H5N1 (AVIAN FLU) NUCLEOPROTEIN |
2X4T | B:1-98; A:182-270; D:182-270; E:1-98 | CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO A PEIODATE-CLEAVABLE PEPTIDE |
2X4U | B:0-99; A:182-270; D:182-270; E:0-99 | CRYSTAL STRUCTURE OF MHC CLASS I HLA-A2.1 BOUND TO HIV-1 PEPTIDE RT468-476 |
2XAC | C:129-226; X:132-226 | STRUCTURAL INSIGHTS INTO THE BINDING OF VEGF-B BY VEGFR-1D2: RECOGNITION AND SPECIFICITY |
2YR3 | A:1-99 | SOLUTION STRUCTURE OF THE FOURTH IG-LIKE DOMAIN FROM MYOSIN LIGHT CHAIN KINASE, SMOOTH MUSCLE |
2YSS | A:1-107; B:1-113 | CRYSTAL STRUCTURE OF HUMANIZED HYHEL-10 FV MUTANT(HQ39KW47Y)-HEN LYSOZYME COMPLEX |
2YXF | A:0-98 | THE HIGH RESOLUTION CRYSTAL STRUCTURE OF BETA2-MICROGLOBULIN UNDER PHYSIOLOGICAL CONDITIONS |
2Z9T | A:0-99 | CRYSTAL STRUCTURE OF THE HUMAN BETA-2 MICROGLOBULIN MUTANT W60G |
2ZCH | L:109-211; L:1-108; H:114-212; H:1-113 | CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY |
2ZCK | L:109-214; L:1-108; H:114-212; H:1-113 | CRYSTAL STRUCTURE OF A TERNARY COMPLEX BETWEEN PSA, A SUBSTRAT-ACYL INTERMEDIATE AND AN ACTIVATING ANTIBODY |
2ZCL | L:109-214; L:1-108; H:114-212; H:1-113 | CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY |
2ZKH | L:108-209; H:117-205; H:1-116 | HUMAN THROMBOPOIETIN NEUTRALIZING ANTIBODY TN1 FAB |
2ZP0 | T:6-105; T:106-210 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D-ILE-GLN-P-AMINOBENZAMIDINE |
2ZWL | T:6-105; T:106-210 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH HIGHLY SELECTIVE PEPTIDE INHIBITOR |
2ZZU | T:6-105; T:106-210 | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-(3-CARBOXYBENZYLOXY)-TRP-GLN-P-AMINOBENZAMIDINE |
3AAZ | B:113-216; A:126-224; H:126-224; A:1-125; H:1-125; L:113-216 | CRYSTAL STRUCTURE OF THE HUMANIZED RECOMBINANT FAB FRAGMENT OF A MURINE; ANTIBODY |
3B2U | D:109-211; D:1-108; G:1-108; K:1-108; L:1-108; O:1-108; R:1-108; U:1-108; X:1-108; H:122-219; J:122-219; N:122-219; Q:122-219; F:122-219; T:122-219; W:122-219; C:122-219; C:1-121; F:1-121; H:1-121; J:1-121; N:1-121; Q:1-121; T:1-121; W:1-121; G:109-211; K:109-211; L:109-211; O:109-211; R:109-211; U:109-211; X:109-211 | CRYSTAL STRUCTURE OF ISOLATED DOMAIN III OF THE EXTRACELLULAR REGION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN COMPLEX WITH THE FAB FRAGMENT OF IMC-11F8 |
3B2V | L:109-211; L:1-108; H:122-220; H:1-121 | CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN COMPLEX WITH THE FAB FRAGMENT OF IMC-11F8 |
3B3I | B:0-99; A:182-276 | CITRULLINATION-DEPENDENT DIFFERENTIAL PRESENTATION OF A SELF-PEPTIDE BY HLA-B27 SUBTYPES |
3B5G | A:1-111; B:1-111 | CRYSTAL STRUCTURE OF THE UNSTABLE AND HIGHLY FIBRILLOGENIC PRO7SER MUTANT OF THE RECOMBINANT VARIABLE DOMAIN 6AJL2 |
3B6S | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE CITRULLINATED VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408) |
3B9V | B:1-112; D:1-112; A:1-112; C:1-112 | CRYSTAL STRUCTURE OF AN AUTONOMOUS VH DOMAIN |
3BDX | A:1-111; B:1-111; C:1-111 | CRYSTAL STRUCTURE OF THE UNSTABLE AND HIGHLY FIBRILLOGENIC PRO7SER MUTANT OF THE RECOMBINANT VARIABLE DOMAIN 6AJL2 |
3BDY | L:109-213; H:116-215; H:0-115; L:1-108 | DUAL SPECIFIC BH1 FAB IN COMPLEX WITH VEGF |
3BE1 | L:109-212; H:116-215; H:1-115; L:1-108 | DUAL SPECIFIC BH1 FAB IN COMPLEX WITH THE EXTRACELLULAR DOMAIN OF HER2/ERBB-2 |
3BFO | A:225-309; B:225-309; C:225-309; D:225-309 | CRYSTAL STRUCTURE OF IG-LIKE C2-TYPE 2 DOMAIN OF THE HUMAN MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATION PROTEIN 1 |
3BGM | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF PKD2 PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2 |
3BH8 | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF RQA_M PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2 |
3BH9 | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF RTY PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2 |
3BHB | B:2-99; A:182-270 | CRYSTAL STRUCTURE OF KMD PHOSPHOPEPTIDE BOUND TO HUMAN CLASS I MHC HLA-A2 |
3BIK | B:33-148; C:30-147 | CRYSTAL STRUCTURE OF THE PD-1/PD-L1 COMPLEX |
3BJ9 | 1:3-118 | CRYSTAL STRUCTURE OF THE SURROGATE LIGHT CHAIN VARIABLE DOMAIN VPREBJ |
3BJL | A:2-111; B:2-111; A:112-212; B:112-212 | LOC, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN AMMONIUM SULFATE |
3BN3 | B:87-196 | CRYSTAL STRUCTURE OF ICAM-5 IN COMPLEX WITH AL I DOMAIN |
3BN9 | E:108-211; F:114-213; D:114-213; D:1-113; F:1-113; C:108-210; C:1-107; E:1-107 | CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH FAB INHIBITOR E2 |
3BO8 | B:0-99; A:182-274 | THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-A1 COMPLEXED WITH THE MAGE-A1 PEPTIDE |
3BP4 | B:0-99; A:182-276 | THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*2705 IN COMPLEX WITH A CATHEPSIN A SIGNAL SEQUENCE PEPTIDE PCATA |
3BP7 | B:0-99; A:182-276 | THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*2709 IN COMPLEX WITH A CATHEPSIN A SIGNAL SEQUENCE PEPTIDE, PCATA |
3BPL | B:-2-96; B:97-199 | CRYSTAL STRUCTURE OF THE IL4-IL4R-COMMON GAMMA TERNARY COMPLEX |
3BPN | B:0-96; B:97-198 | CRYSTAL STRUCTURE OF THE IL4-IL4R-IL13RA TERNARY COMPLEX |
3BPO | B:-1-96; B:97-196 | CRYSTAL STRUCTURE OF THE IL13-IL4R-IL13RA TERNARY COMPLEX |
3BSZ | L:113-215; L:1-112; M:1-112; H:119-215; N:119-215; M:113-215; H:1-118; N:1-118 | CRYSTAL STRUCTURE OF THE TRANSTHYRETIN-RETINOL BINDING PROTEIN-FAB COMPLEX |
3BT2 | L:108-210; H:115-208; H:1-114; L:1-107 | STRUCTURE OF UROKINASE RECEPTOR, UROKINASE AND VITRONECTIN COMPLEX |
3BVN | B:1-99; E:1-99; A:182-272; D:182-272 | HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*1402 IN COMPLEX WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS |
3BW9 | B:0-99; A:182-272 | CRYSTAL STRUCTURE OF HLA B*3508 IN COMPLEX WITH A HCMV 12-MER PEPTIDE FROM THE PP65 PROTEIN |
3BWA | B:0-99; A:182-272 | CRYSTAL STRUCTURE OF HLA B*3508 IN COMPLEX WITH A HCMV 8-MER PEPTIDE FROM THE PP65 PROTEIN |
3BX7 | C:3-122 | ENGINEERED HUMAN LIPOCALIN 2 (LCN2) IN COMPLEX WITH THE EXTRACELLULAR DOMAIN OF HUMAN CTLA-4 |
3BXN | B:1-99; A:182-272 | THE HIGH RESOLUTION CRYSTAL STRUCTURE OF HLA-B*1402 COMPLEXED WITH A CATHEPSIN A SIGNAL SEQUENCE PEPTIDE, PCATA |
3BZE | B:0-99; A:182-272; C:182-272; G:182-272; E:182-272; D:0-99; F:0-99; H:0-99 | THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E |
3BZF | B:3-99; A:182-272; C:182-272; D:3-99 | THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E |
3C2A | H:114-223; I:114-223; L:2-107; M:2-107; L:108-211; M:108-211; H:1-113; I:1-113 | ANTIBODY FAB FRAGMENT 447-52D IN COMPLEX WITH UG1033 PEPTIDE |
3C2S | A:338-443; A:238-337 | STRUCTURAL CHARACTERIZATION OF A HUMAN FC FRAGMENT ENGINEERED FOR LACK OF EFFECTOR FUNCTIONS |
3C5J | A:82-180; B:94-190 | CRYSTAL STRUCTURE OF HLA DR52C |
3C9N | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF A SARS CORONA VIRUS DERIVED PEPTIDE BOUND TO THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I MOLECULE HLA-B*1501 |
3CAF | A:154-249 | CRYSTAL STRUCTURE OF HFGFR2 D2 DOMAIN |
3CD4 | A:1-98; A:99-173 | REFINEMENT AND ANALYSIS OF THE FIRST TWO DOMAINS OF HUMAN CD4 |
3CDG | B:0-99; A:182-272; C:182-272; D:0-99 | HUMAN CD94/NKG2A IN COMPLEX WITH HLA-E |
3CDY | A:0-107; B:0-107 | AL-09 H87Y, IMMUNOGLOBULIN LIGHT CHAIN VARIABLE DOMAIN |
3CIQ | G:0-98; A:0-97; B:0-97; C:0-97; D:0-97; E:0-97; F:0-97; I:0-97; J:0-97; K:0-97; L:0-97; H:0-97 | A REGULATABLE SWITCH MEDIATES SELF-ASSOCIATION IN AN IMMUNOGLOBULIN FOLD |
3CNK | A:2559-2647; B:2559-2647 | CRYSTAL STRUCTURE OF THE DIMERIZATION DOMAIN OF HUMAN FILAMIN A |
3CSY | B:108-211; A:114-228; C:114-228; E:114-228; G:114-228; B:1-107; D:1-107; F:1-107; H:1-107; A:1-113; C:1-113; E:1-113; G:1-113; D:108-211; F:108-211; H:108-211 | CRYSTAL STRUCTURE OF THE TRIMERIC PREFUSION EBOLA VIRUS GLYCOPROTEIN IN COMPLEX WITH A NEUTRALIZING ANTIBODY FROM A HUMAN SURVIVOR |
3CU1 | A:154-249; C:154-249 | CRYSTAL STRUCTURE OF 2:2:2 FGFR2D2:FGF1:SOS COMPLEX |
3CXE | | [entry was replaced by entry 4NKQ without any CATH domain information] |
3D0L | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 BROADLY NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH THE GP41 FP-MPER HYB3K CONSTRUCT 514GIGALFLGFLGAAGS528KK-AHX-655KNEQELLELDKWASLWN671 |
3D0V | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING MONOCLONAL ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE LLELDKWASLW |
3D18 | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH A VARIANT OF THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2(L)) OF EPSTEIN-BARR VIRUS |
3D25 | B:2-99; A:182-270 | CRYSTAL STRUCTURE OF HA-1 MINOR HISTOCOMPATIBILITY ANTIGEN BOUND TO HUMAN CLASS I MHC HLA-A2 |
3D48 | R:2-101; R:102-204 | CRYSTAL STRUCTURE OF A PROLACTIN RECEPTOR ANTAGONIST BOUND TO THE EXTRACELLULAR DOMAIN OF THE PROLACTIN RECEPTOR |
3D5O | F:87-171; F:1-86 | STRUCTURAL RECOGNITION AND FUNCTIONAL ACTIVATION OF FCRR BY INNATE PENTRAXINS |
3D6G | A:338-443; B:338-443; A:238-337; B:238-337 | FC FRAGMENT OF IGG1 (HERCEPTIN) WITH PROTEIN-A MIMETIC PEPTIDE DENDRIMER LIGAND. |
3D85 | A:109-213; B:116-215; B:1-115; D:103-210; D:1-84; D:214-304; A:1-108 | CRYSTAL STRUCTURE OF IL-23 IN COMPLEX WITH NEUTRALIZING FAB |
3D87 | B:103-210; D:103-210; B:1-84; D:1-84; B:214-304; D:214-304 | CRYSTAL STRUCTURE OF INTERLEUKIN-23 |
3DAR | A:154-249; B:154-249 | CRYSTAL STRUCTURE OF D2 DOMAIN FROM HUMAN FGFR2 |
3DHJ | A:0-99 | BETA 2 MICROGLOBULIN MUTANT W60C |
3DHM | A:0-99 | BETA 2 MICROGLOBULIN MUTANT D59P |
3DI2 | B:109-211; D:109-209 | CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN INTERLEUKIN-7 WITH UNGLYCOSYLATED HUMAN INTERLEUKIN-7 RECEPTOR ALPHA ECTODOMAIN |
3DI3 | B:109-209 | CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN INTERLEUKIN-7 WITH GLYCOSYLATED HUMAN INTERLEUKIN-7 RECEPTOR ALPHA ECTODOMAIN |
3DJ9 | A:236-342 | CRYSTAL STRUCTURE OF AN ISOLATED, UNGLYCOSYLATED ANTIBODY CH2 DOMAIN |
3DRO | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 CROSS NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH GP41 PEPTIDE ELLELDKWASLWN GROWN IN AMMONIUM SULFATE |
3DRQ | A:108-211; B:114-213; B:1-113; A:1-107 | CRYSTAL STRUCTURE OF THE HIV-1 BROADLY NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH THE GP41 FP-MPER HYB3K CONSTRUCT 514GIGALFLGFLGAAGS528KK-AHX-655KNEQELLELDKWASLWN671 SOAKED IN PEG/2-PROPANOL SOLUTION |
3DRT | A:108-211; B:114-213; B:1-113 | CRYSTAL STRUCTURE OF THE HIV-1 BROADLY NEUTRALIZING ANTIBODY 2F5 IN COMPLEX WITH THE GP41 SCRAMBLEDFP-MPER SCRHYB3K CONSTRUCT GIGAFGLLGFLAAGSKK-AHX-K656NEQELLELDKWASLWN671 |
3DTX | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE DOUBLE CITRULLINATED VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408) |
3DUH | B:103-210; A:103-210; B:-1-84; A:0-84; A:214-304; B:214-304 | STRUCTURE OF INTERLEUKIN-23 |
3DVG | A:111-214; B:121-221; B:1-120; A:5-110 | CRYSTAL STRUCTURE OF K63-SPECIFIC FAB APU.3A8 BOUND TO K63-LINKED DI-UBIQUITIN |
3DVN | A:111-216; B:121-221; H:121-221; B:1-120; H:1-120; L:111-216; A:5-110; L:5-110 | CRYSTAL STRUCTURE OF K63-SPECIFIC FAB APU2.16 BOUND TO K63-LINKED DI-UBIQUITIN |
3DX6 | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF B*4402 PRESENTING A 10MER EBV EPITOPE |
3DX7 | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*4403 PRESENTING 10MER EBV ANTIGEN |
3DX8 | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF B*4405 PRESENTING A 10MER EBV EPITOPE |
3DX9 | A:2-125; C:2-125; B:2-128; D:2-128; B:129-257; D:129-257 | CRYSTAL STRUCTURE OF THE DM1 TCR AT 2.75A |
3DXA | B:1-99; D:2-125; I:2-125; N:2-125; E:2-128; J:2-128; O:2-128; E:129-257; J:129-257; O:129-257; G:1-99; L:1-99; A:182-272; F:182-272; K:182-272 | CRYSTAL STRUCTURE OF THE DM1 TCR IN COMPLEX WITH HLA-B*4405 AND DECAMER EBV ANTIGEN |
3EKC | A:0-99 | STRUCTURE OF W60V BETA-2 MICROGLOBULIN MUTANT |
3ELA | T:6-105; T:106-209 | CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA MUTANT IN COMPLEX WITH SOLUBLE TISSUE FACTOR |
3ES6 | A:184-273 | CRYSTAL STRUCTURE OF THE NOVEL COMPLEX FORMED BETWEEN ZINC 2-GLYCOPROTEIN (ZAG) AND PROLACTIN INDUCIBLE PROTEIN (PIP) FROM HUMAN SEMINAL PLASMA |
3EUU | A:154-249; B:154-249 | CRYSTAL STRUCTURE OF THE FGFR2 D2 DOMAIN |
3EW3 | B:0-101; C:4-101; B:102-202; C:102-201 | THE 1:2 COMPLEX BETWEEN A NTERMINAL ELONGATED PROLACTIN AND THE EXTRA CELLULAR DOMAIN OF THE RAT PROLACTIN RECEPTOR |
3F7P | C:1217-1330; C:1127-1216 | CRYSTAL STRUCTURE OF A COMPLEX BETWEEN INTEGRIN BETA4 AND PLECTIN |
3FCT | C:109-211; B:115-214; D:115-214; A:109-213; A:1-108; C:1-108; B:1-114; D:1-114 | MATURE METAL CHELATASE CATALYTIC ANTIBODY WITH HAPTEN |
3FFC | B:0-99; E:2-131; J:2-131; E:132-260; J:132-260; G:0-99; D:3-122; I:3-122; A:182-272; F:182-272 | CRYSTAL STRUCTURE OF CF34 TCR IN COMPLEX WITH HLA-B8/FLR |
3FJT | A:338-443; B:338-443; A:238-337; B:238-337 | CRYSTAL STRUCTURE OF A HUMAN FC FRAGMENT ENGINEERED FOR EXTENDED SERUM HALF-LIFE |
3FQN | B:1-98; A:182-270 | PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES |
3FQR | B:1-98; A:182-270 | PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES |
3FQT | B:1-98; A:182-270 | PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES |
3FQU | B:1-98; A:182-270 | PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES |
3FQW | B:1-98; A:182-270 | PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES |
3FQX | B:1-98; A:182-270 | PHOSPHORYLATION OF SELF-PEPTIDES ALTERS HUMAN LEUKOCYTE ANTIGEN CLASS I-RESTRICTED ANTIGEN PRESENTATION AND GENERATES TUMOR SPECIFIC EPITOPES |
3FT2 | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF A CITRULLINE PEPTIDE VARIANT OF THE MINOR HISTOCOMPATIBILITY PEPTIDE HA-1 IN COMPLEX WITH HLA-A2 |
3FT3 | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF THE MINOR HISTOCOMPATIBILITY PEPTIDE HA-1HIS IN COMPLEX WITH HLA-A2 |
3FT4 | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF THE MINOR HISTOCOMPATIBILITY PEPTIDE HA-1ARG IN COMPLEX WITH HLA-A2 |
3FZU | D:108-211; H:119-219; C:119-219; C:1-118; H:1-118; L:108-211 | IGG1 FAB CHARACTERIZED BY H/D EXCHANGE |
3G04 | B:114-213; B:1-113; A:108-208 | CRYSTAL STRUCTURE OF THE TSH RECEPTOR IN COMPLEX WITH A THYROID-STIMULATING AUTOANTIBODY |
3G6A | B:123-222; H:123-222; B:1-122; H:1-122 | CRYSTAL STRUCTURE OF ANTI-IL-13 ANTIBODY CNTO607 |
3G6D | H:123-223; H:1-122 | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN CNTO607 FAB AND IL-13 |
3G6J | E:109-214; F:114-213; H:114-213; F:1-113; H:1-113; G:109-214 | C3B IN COMPLEX WITH A C3B SPECIFIC FAB |
3GHB | H:114-211; I:114-211; H:1-113; I:1-113 | CRYSTAL STRUCTURE OF ANTI-HIV-1 FAB 447-52D IN COMPLEX WITH V3 PEPTIDE W2RW020 |
3GHE | H:114-211; H:1-113 | CRYSTAL STRUCTURE OF ANTI-HIV-1 FAB 537-10D IN COMPLEX WITH V3 PEPTIDE MN |
3GIV | B:0-99; A:182-270; D:182-270; E:0-99 | ANTIGEN PROCESSING INFLUENCES HIV-SPECIFIC CYTOTOXIC T LYMPHOCYTE IMMUNODOMINANCE |
3GIZ | L:109-211; H:123-222; H:1-122 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ANTI-CD20 ANTIBODY OFATUMUMAB |
3GJE | B:120-219; H:120-219; B:1-119; H:1-119 | RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES |
3GJF | B:0-99; A:182-270; D:182-270; H:120-219; M:120-219; H:1-119; M:1-119; E:0-99 | RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES |
3GKW | L:109-207; H:108-212; H:6-107 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF NIMOTUZUMAB. AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY |
3GRW | L:109-214; H:114-216; H:1-113 | FGFR3 IN COMPLEX WITH A FAB |
3GSN | L:0-99; H:182-270 | CRYSTAL STRUCTURE OF THE PUBLIC RA14 TCR IN COMPLEX WITH THE HCMV DOMINANT NLV/HLA-A2 EPITOPE |
3GSO | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV PEPTIDE |
3GSQ | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5S PEPTIDE VARIANT |
3GSR | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5V PEPTIDE VARIANT |
3GSU | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5T PEPTIDE VARIANT |
3GSV | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5Q PEPTIDE VARIANT |
3GSW | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-T8A PEPTIDE VARIANT |
3GSX | B:0-99; A:182-270 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-T8V PEPTIDE VARIANT |
3H0T | B:123-220; B:1-122 | HEPCIDIN-FAB COMPLEX |
3H3B | C:138-244; D:138-244 | CRYSTAL STRUCTURE OF THE SINGLE-CHAIN FV (SCFV) FRAGMENT OF AN ANTI-ERBB2 ANTIBODY CHA21 IN COMPLEX WITH RESIDUES 1-192 OF ERBB2 EXTRACELLULAR DOMAIN |
3H42 | H:124-224; H:1-123 | CRYSTAL STRUCTURE OF PCSK9 IN COMPLEX WITH FAB FROM LDLR COMPETITIVE ANTIBODY |
3H7B | B:0-99; E:0-99; A:182-270; D:182-270 | HUMAN CLASS I MHC HLA-A2 IN COMPLEX WITH THE TEL1P PEPTIDE |
3H8N | A:103-200; A:6-102 | CRYSTAL STRUCTURE ANALYSIS OF KIR2DS4 |
3H9H | B:0-99; D:182-270; A:183-270; E:0-99 | HUMAN CLASS I MHC HLA-A2(A150P) IN COMPLEX WITH THE TEL1P PEPTIDE |
3H9S | B:0-99; A:182-270; D:1-116 | THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND TEL1P PEPTIDE |
3H9Y | A:436-543; B:436-543; E:436-543; B:335-435; A:336-435; E:336-435 | CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS |
3H9Z | A:436-543; B:436-543; C:436-543; D:436-543; A:336-435; B:336-435; C:336-435; D:336-435 | CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS |
3HA0 | A:436-543; B:436-543; C:436-543; D:436-543; E:436-543; F:436-543; A:336-435; B:336-435; C:336-435; D:336-435; E:336-435; F:336-435 | CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS |
3HAE | B:0-99; A:182-270; D:182-270; J:182-270; P:182-270; H:120-219; I:120-219; O:120-219; T:120-219; G:111-211; L:111-211; N:111-211; S:111-211; H:1-119; I:1-119; O:1-119; T:1-119; E:0-99; K:0-99; Q:0-99 | RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES |
3HC0 | B:109-211; H:117-217; A:117-216; A:1-116; H:1-116; L:109-211 | BHA10 IGG1 WILD-TYPE FAB - ANTIBODY DIRECTED AT HUMAN LTBR |
3HC3 | L:109-211; H:117-217; H:1-116 | BHA10 IGG1 FAB DOUBLE MUTANT VARIANT - ANTIBODY DIRECTED AT HUMAN LTBR |
3HC4 | L:109-211; H:117-217; H:1-116 | BHA10 IGG1 FAB QUADRUPLE MUTANT VARIANT - ANTIBODY DIRECTED AT HUMAN LTBR |
3HCV | B:0-99; A:182-276 | CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE DOUBLE CITRULLINATED VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VIPR) PEPTIDE (RESIDUES 400-408) |
3HG1 | B:0-99; A:182-270; D:2-109 | GERMLINE-GOVERNED RECOGNITION OF A CANCER EPITOPE BY AN IMMUNODOMINANT HUMAN T CELL RECEPTOR |
3HHR | B:132-234; C:132-232; B:32-131; C:32-131 | HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX |
3HI5 | L:107-210; H:121-220; H:2-120 | CRYSTAL STRUCTURE OF FAB FRAGMENT OF AL-57 |
3HI6 | L:107-210; X:121-220; H:121-220; H:1-120; X:1-120; Y:107-210 | CRYSTAL STRUCTURE OF INTERMEDIATE AFFINITY I DOMAIN OF INTEGRIN LFA-1 WITH THE FAB FRAGMENT OF ITS ANTIBODY AL-57 |
3HLA | B:1-99; A:182-270 | HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2.1 |
3HMW | L:108-214; H:120-221; H:1-119 | CRYSTAL STRUCTURE OF USTEKINUMAB FAB |
3HMX | L:108-214; H:120-220; H:1-119; A:103-210; A:1-84; A:214-304 | CRYSTAL STRUCTURE OF USTEKINUMAB FAB/IL-12 COMPLEX |
3HUJ | D:1-99; E:1-116; G:1-116; B:1-97; A:183-280; C:183-278 | CRYSTAL STRUCTURE OF HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE IN COMPLEX WITH SEMI-INVARIANT NKT CELL RECEPTOR |
3I6G | B:0-99; A:182-270; D:182-270; E:0-99 | NEWLY IDENTIFIED EPITOPE MN2 FROM SARS-COV M PROTEIN COMPLEXED WITHHLA-A*0201 |
3I6K | B:0-99; A:182-270; E:182-270; F:0-99 | NEWLY IDENTIFIED EPITOPE FROM SARS-COV MEMBRANE PROTEIN COMPLEXED WITH HLA-A*0201 |
3IXA | B:0-99; A:183-270; D:183-270; E:0-99 | HUMAN CLASS I MHC HLA-A2(A150P) IN COMPLEX WITH THE TAX PEPTIDE |
3JUY | A:1-126; C:1-127; D:1-127; E:1-127; F:1-127; B:1-130 | CRYSTAL STRUCTURE OF A 3B3 VARIANT, A BROADLY NEUTRALIZING HIV-1 SCFV ANTIBODY |
3K2M | C:1-101; D:1-101 | CRYSTAL STRUCTURE OF MONOBODY HA4/ABL1 SH2 DOMAIN COMPLEX |
3K2U | L:109-214; H:114-216; H:1-113 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC INHIBITORY ANTIBODY FAB40 |
3KJ6 | L:109-211; H:115-217; H:1-114 | CRYSTAL STRUCTURE OF A METHYLATED BETA2 ADRENERGIC RECEPTOR-FAB COMPLEX |
3KLA | B:0-99; E:0-99; A:182-270; D:182-270 | CA2+ RELEASE FROM THE ENDOPLASMIC RETICULUM OF NY-ESO-1 SPECIFIC T CELLS IS MODULATED BY THE AFFINITY OF T CELL RECEPTOR AND BY THE USE OF THE CD8 CO-RECEPTOR |
3KPL | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA B*4402 IN COMPLEX WITH EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN |
3KPM | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA B*4402 IN COMPLEX WITH EEYLKAWTF, A MIMOTOPE |
3KPN | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA B*4403 IN COMPLEX WITH EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN |
3KPO | B:0-99; A:182-272 | CRYSTAL STRUCTURE OF HLA B*4403 IN COMPLEX WITH EEYLKAWTF, A MIMOTOPE |
3KPP | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA B*4405 IN COMPLEX WITH EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN |
3KPQ | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA B*4405 IN COMPLEX WITH EEYLKAWTF, A MIMOTOPE |
3KPR | B:1-99; D:2-116; I:2-116; G:1-99; A:182-272; F:182-272 | CRYSTAL STRUCTURE OF THE LC13 TCR IN COMPLEX WITH HLA B*4405 BOUND TO EEYLKAWTF A MIMOTOPE |
3KPS | B:1-99; D:2-116; A:182-272 | CRYSTAL STRUCTURE OF THE LC13 TCR IN COMPLEX WITH HLA B*4405 BOUND TO EEYLQAFTY A SELF PEPTIDE FROM THE ABCD3 PROTEIN |
3KR3 | L:109-212; H:123-222; H:1-122 | CRYSTAL STRUCTURE OF IGF-II ANTIBODY COMPLEX |
3KWW | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF THE 'RESTRICTION TRIAD' MUTANT OF HLA B*3508, BETA-2-MICROGLOBULIN AND EBV PEPTIDE |
3KXF | B:1-99; F:1-99; J:1-99; L:1-99; D:1-114; G:1-114; M:1-114; N:1-114; A:182-272; C:182-272; I:182-272; K:182-272 | CRYSTAL STRUCTURE OF SB27 TCR IN COMPLEX WITH THE 'RESTRICTION TRIAD' MUTANT HLA-B*3508-13MER |
3KYK | L:109-211; H:120-220; H:1-119 | CRYSTAL STRUCTURE OF LI33 IGG1 FAB |
3KYN | B:0-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-G PRESENTING KGPPAALTL PEPTIDE |
3KYO | B:0-99; A:182-272; C:182-272; D:0-99 | CRYSTAL STRUCTURE OF HLA-G PRESENTING KLPAQFYIL PEPTIDE |
3L3D | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE F3A MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201 |
3L3G | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE R5A MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201 |
3L3I | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE F7A MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201 |
3L3J | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE F3A/R5A DOUBLE MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201 |
3L3K | B:1-99; A:182-272 | CRYSTAL STRUCTURE OF HLA-B*4402 IN COMPLEX WITH THE R5A/F7A DOUBLE MUTANT OF A SELF-PEPTIDE DERIVED FROM DPA*0201 |
3L5X | L:109-214; H:122-220; H:2-121 | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN IL-13 AND H2L6 FAB |
3L5Y | | [entry was replaced by entry 4PS4 without any CATH domain information] |
3L6F | A:82-180; B:93-190 | STRUCTURE OF MHC CLASS II MOLECULE HLA-DR1 COMPLEXED WITH PHOSPHOPEPTIDE MART-1 |
3LVE | A:1-108 | LEN Q38E MUTANT: A DOMAIN FLIP FROM A SINGLE AMINO ACID SUBSTITUTION |
3MCG | 1:2-111; 2:2-111; 1:112-216; 2:112-212 | THREE-DIMENSIONAL STRUCTURE OF A LIGHT CHAIN DIMER CRYSTALLIZED IN WATER. CONFORMATIONAL FLEXIBILITY OF A MOLECULE IN TWO CRYSTAL FORMS |
4BJL | A:2-111; B:2-111; A:112-212; B:112-210 | LOCW, A LAMBDA 1 TYPE LIGHT-CHAIN DIMER (BENCE-JONES PROTEIN) CRYSTALLIZED IN DISTILLED WATER |
4LVE | B:301-407; A:1-108 | LEN K30T MUTANT: A DOMAIN FLIP AS A RESULT OF A SINGLE AMINO ACID SUBSTITUTION |
5LVE | A:1-108 | STRUCTURE OF THE VARIABLE DOMAIN OF HUMAN IMMUNOGLOBULIN K-4 LIGHT CHAIN LEN |
7FAB | H:118-216; L:1-103; H:1-117; L:104-204 | CRYSTAL STRUCTURE OF HUMAN IMMUNOGLOBULIN FRAGMENT FAB NEW REFINED AT 2.0 ANGSTROMS RESOLUTION |
8FAB | D:122-221; B:122-222; A:3-107; C:3-107; A:108-208; C:108-208; B:1-121; D:1-121 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT FROM THE HUMAN MYELOMA IMMUNOGLOBULIN IGG HIL AT 1.8 ANGSTROMS RESOLUTION |